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Abstract 
Heart failure (HF) is highly prevalent and associated with high mortality in chronic 
kidney disease (CKD). Although the cardiac structural alterations in CKD had been 
well studied, the pathophysiology of cardiac dysfunction in CKD, especially in the 
early asymptomatic stage, is not well understood. Identification of early cardiac 
dysfunction and an understanding of the pathophysiology of such dysfunction are 
vital in preventing the emergence and progression of HF in CKD.  
The hypothesis underlying this thesis is that CPOmax (peak cardiac power output) and 
cardiac functional reserve are impaired in asymptomatic CKD patients even in the 
absence of any known cardiac diseases or diabetes.  
Asymptomatic CKD patients without primary cardiac diseases or diabetes mellitus 
were tested. CPOmax, a direct indicator of cardiac performance, was measured non-
invasively using specialised cardiopulmonary exercise test. In addition, the 
reversibility of subclinical cardiac dysfunction after kidney transplantation was 
evaluated. Furthermore, to obtain mechanistic insights, the relationship between 
subclinical cardiac dysfunction and serum uraemic toxin concentrations, and the 
direct effect of a prototype uraemic toxin on the mechanical properties of isolated 
rodent cardiomyocytes were also evaluated. 
Compared to healthy controls, the CKD patients showed a graded reduction in 
CPOmax across different stages of CKD. The impairment was found to be reversible 
with kidney transplantation. The impairment correlated with total and free serum 
concentrations of indoxyl sulphate (IXS), a protein bound uraemic toxin. Further in 
vitro evaluation showed that IXS had direct physiological effects on cardiomyocytes 
and was shown to act through pathway involving protein kinase-A akin to the 
mechanism of action of sympathomimetics.  
In conclusion, this reverse translational research has demonstrated for the first time 
that CKD per se causes impairment of peak cardiac power output and thereby cardiac 
functional reserve in vivo, and unravelled a novel mechanism of cardiotoxicity 
mediated by a protein-bound uraemic toxin in vitro. 
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INTRODUCTION & BACKGROUND 
1.1 Overview 
1.1.1 The role of kidneys 
The first reference to kidneys in the western literature was by Aristotle (384-322 BC) 
in his works Historia Animalium and De Partibus Animalium. According to 
Aristotle, the kidneys’ role was to separate surplus liquid from the blood to form 
‘residuum’. Through the works of Bellini and Malpighi in the 17th century, and 
Henle and Bowman in the 19th century a clear understanding of the structure of the 
kidney emerged. The discoveries over the last century helped improve our 
knowledge of the function of kidney and further research to clarify the finer 
functions of the kidney are still underway. 
 The kidneys’ principal role is elimination of metabolic waste and the 
regulation of the volume and composition of body fluid. The functional unit of 
kidney is the nephron composed of glomerulus, formed by the invagination of a tuft 
of capillaries, and the tubules. There are approximately one million nephrons in each 
kidney and the kidneys receive nearly a quarter of the cardiac output. The hydrostatic 
pressure difference between the capillaries and the urinary space drives ultrafiltration 
at the rate of 120 – 130 ml/min which is the glomerular filtration rate. An estimate of 
this glomerular filtration rate (GFR) serves as a measure of kidneys’ function. 
Kidney disease ensues when the kidneys’ function drops and the degree of drop in 
GFR helps quantify the severity of the kidney disease.1  
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1.1.2 The interaction between kidney disease and heart disease  
The first observations of the effect of kidney disease on the heart was by Richard 
Bright (1789- 1858) who documented that cardiac hypertrophy was a common 
anomaly resulting from chronic kidney disease.2 The cardiac hypertrophy was 
thought to be a consequence of rise in blood pressure seen in kidney disease. 
Alfred Stengel in 1914 proposed a definition for ‘cardio-renal disease’ 
“When this combination of symptoms is of such character that the observer 
cannot readily assign to either the cardiovascular system or to the kidneys 
the preponderance of responsibility, the term "cardio-renal disease" is often 
employed”.3 
In the same year (1914) Oskar Klotz wrote a review on cardio-renal interaction in the 
Canadian Medical Association journal titled ‘The Triple Alliance: Heart, Kidney and 
Arterial Disease’.4 In the article, the author described the lesions in the heart, kidney 
and arteries as ‘sclerosis’ and listed several possible mechanisms that led to the 
disease of the heart when kidney disease was the primary pathology. This included 
high blood pressure and direct chemical irritation on the heart by retained products of 
metabolism. The paper also highlighted the possibility of greater production of 
adrenalin in chronic kidney disease affecting the heart. 
In 1940, Gouley first coined the term ‘uraemic myocardiopathy’5 and later 
Langendorf and Pirani showed that interstitial widening and fibrosis were common 
in hearts of patients dying from uraemia.6 
The full extent of the problem of cardiovascular disease in chronic kidney 
disease and end stage renal disease was described in the 1990’s through 
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epidemiological observations.7-9 The studies showed that a large proportion of 
patients starting dialysis already suffer from cardiac abnormalities and dysfunction 
and consequently suffered a poor prognosis. In 2003, a statement from the American 
Heart Association (AHA) was published in Hypertension and Circulation 
underscoring the problem of increased cardiovascular risk in chronic kidney disease, 
and the lack of knowledge on pathophysiology.10 This set the stage for the renewed 
enthusiasm in understanding the cardiac disease of chronic kidney disease over 150 
years after its first description by Bright. 
 In this introductory chapter I shall present a review of current literature 
describing how kidneys’ function/dysfunction is assessed and how kidney disease is 
classified into different stages of severity; what is the extent of heart disease in 
kidney disease; what is our current understanding of the nature of heart disease in 
kidney disease and finally highlight the gaps in knowledge. 
1.2 Overview of Chronic Kidney Disease  
1.2.1 Measuring kidney function/dysfunction 
The filtering units of the kidneys, the glomeruli, filter approximately 180 l/day or 
~125 ml/min which is called the glomerular filtration rate (GFR).1 In health the GFR 
is maintained at a constant level due to autoregulatory mechanisms in the kidney. In 
disease, with a reduction in intrarenal blood flow, damage or loss of glomeruli or 
tubules, or obstruction to the free flow of ultrafiltrate along the tubules, the GFR will 
fall, and the ability to eliminate metabolic waste and to regulate the volume and 
composition of body fluid will decline. This will manifest as a rise in the blood levels 
of various solutes such as urea, creatinine etc and reduction in measured GFR. 
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 The GFR can be obtained by measuring the excretion and plasma level of 
a substance that is freely filtered through the glomeruli and neither secreted nor 
reabsorbed by the tubules. The amount of such a substance in the urine per unit time 
must have been produced by filtering exactly the number of millilitres of plasma that 
contained this amount. This value is called the clearance for the substance. Inulin, a 
polymer of fructose, meets the criteria for a substance that is freely filtered and 
neither secreted nor reabsorbed and inulin clearance has been extensively used in 
experimental setting to measure GFR. In the clinical setting, the endogenous 
creatinine clearance serves as a convenient alternative. Creatinine is a product of 
degradation of creatine phosphate in muscle. It is generated at a constant rate in the 
body and excreted by the kidneys. Although some creatinine is secreted by the 
tubules and some absorbed by the tubules, the creatinine clearance values agree 
closely with that of inulin clearance. The GFR in a normal sized man is 
approximately 125 ml/min and its magnitude correlates well with the body surface 
area.1 
 As 24 h urine collection can be cumbersome, several equations are 
utilised nowadays to produce an estimated GFR (eGFR). The estimation equations 
incorporate clinical and demographic variables such as age, gender, race or lean body 
weight. The Modification of Diet in Renal Disease (MDRD) formula with 4 
variables (serum creatinine, gender, race and age) is widely used in clinical practice 
and was utilised to estimate GFR in the present study as well.11 Limitations in using 
eGFR include conditions where there is altered creatinine production (vegetarian 
diet, reduced muscle mass etc) and in some patient groups such as diabetics with 
high GFR, pregnant women, patients with morbid obesity etc. In these settings 
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creatinine clearance or clearance of an exogenous marker may be required to assess 
kidney function.11 
1.2.2 Definition and classification of chronic kidney disease 
The Renal National Service Framework has adopted the definition and classification 
of chronic kidney disease (CKD) proposed by US National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (NKF-KDOQI).12 This classification 
divides CKD into five stages (Table 1.1) defined by evidence of kidney damage and 
level of renal function as measured by glomerular filtration rate (GFR). 
 
Table: 1.1 Stages of chronic kidney disease 
 
Stage 
 
Description 
 
GFR (ml/min/1.73m2)  
 
1 Kidney damage with normal or increased 
GFR 
≥90 
2 Kidney damage with mild reduction in GFR 60–89 
3 Moderate reduction in GFR 30–59 
4 Severe reduction in GFR 15–29 
5 Kidney failure  <15 (or on dialysis) 
  
  
Stages 3–5 may be defined by GFR alone, whilst stages 1 and 2 also require the 
presence of persistent proteinuria, albuminuria, haematuria or structural 
abnormalities. Stage 3 was later subdivided into 3a (GFR 45-60) and 3b (GFR 30-
45).12 Stage 5 CKD may be described as established renal failure. Patients are said to 
be in end stage renal disease (ESRD) when CKD has progressed so far that renal 
replacement therapy (regular dialysis treatment or kidney transplantation) may be 
required to maintain life. In clinical practice, the GFR measurements are estimated 
measurements (eGFR) based on serum creatinine concentration. The Modification of 
Diet in Renal Disease (MDRD) formula is widely used.11 Since the commencement 
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of the present study, eGFR based on CKD Epidemiology Collaboration (CKD-EPI) 
equation13 and classification of CKD into grades14 instead of stages have been slowly 
gaining prominence.  
1.2.3 Epidemiology of CKD 
Information on the prevalence of CKD in the UK is limited. However, data from 
National Health and Nutrition Examination Surveys (NHANES) in the USA gives an 
idea of the prevalence of CKD in general population. Data from the NHANES 2003 
to 2006 database, with GFR estimated with the CKD-EPI equation, showed that the 
overall prevalence of CKD stages 1 through 5 is 14.2 percent.15 Data from a large 
primary care study (NEORICA) in the UK suggests an age-adjusted prevalence of 
CKD 3-5 of 8.5%. 
1.2.4 Complications of chronic kidney disease 
The common complications of CKD include disorders of fluid and electrolytes, 
mineral and bone disorder, anaemia, hypertension, dyslipidaemia, endocrine 
abnormalities and cardiovascular disease. The relative risks of such complications 
increase with increasing severity of CKD. 
1.2.5 Heart-kidney interaction 
Although an association between cardiac and renal disease was observed in Richard 
Bright’s seminal work,16 research over the past 2 decades has uncovered several 
facets of this interaction and culminated in the classification of such interactions into 
5 distinct types of cardio-renal syndromes (CRS) (Table 1.2).17 
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Table 1.2 Classification of cardio-renal syndromes 
Syndrome Definition 
Acute cardio-renal (type 1) Acute worsening of heart function leading to 
kidney injury and/or dysfunction 
Chronic cardio-renal (type 2) Chronic abnormalities in heart function leading to 
kidney injury or dysfunction 
Acute reno-cardiac (type 3) Acute worsening of kidney function leading to 
heart injury and/or dysfunction 
Chronic reno-cardiac (type 4) Chronic kidney disease (CKD) leading to heart 
injury, disease and/or dysfunction 
Secondary CRS (type 5) Systemic conditions leading to simultaneous 
injury and/or dysfunction of heart and kidney (e.g. 
sepsis amyloidosis, etc.) 
 
The present study focuses on type 4 CRS or chronic reno-cardiac syndrome where 
CKD, with its unique uraemic milieu, leads to the emergence of cardiovascular 
disease. The studies presented in this thesis specifically aims at improving our 
understanding of the cardiac dysfunction that occurs in CKD. 
1.3 Epidemiology of cardiovascular disease in chronic kidney disease 
1.3.1 CVD morbidity in CKD 
CKD is a state of high cardiovascular morbidity and mortality. It was believed that 
the high prevalence of cardiovascular disease (CVD) in CKD is secondary to shared 
risk factors such as smoking, hypertension, diabetes mellitus, hyperlipidaemia, etc. 
However, CKD is increasingly being recognised as an independent risk factor for 
cardiovascular disease.18-20 Cardiac disease of CKD originates early18 and progresses 
relentlessly with increasing severity of CKD. The CV risk increases from 2 to 4-fold 
at stage 3 CKD to 10 to 50-fold at stage 5 compared to general population (Table 
1.3).21 The younger the patient, higher the relative risk. 
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Table 1.3 CVD risk according to stages of CKD21 
Stages CV risk (odds ratio) 
2 1.5 
3 2 to 4 
4 4 to 10 
5 10 to 50 
ESRD 20 to 1000 
 
1.3.2 Different types of CVD in CKD 
Data from United States Renal Data System (USRDS) shows the prevalence of 
different types of CVD in CKD and ESRD patients in US Medicare (≥ 65years) 
population (Table 1.4). Heart failure (as per coding for hospital admission with 
symptomatic heart failure) is the predominant cardiac abnormality of CKD with a 
prevalence of 44% in pre dialysis CKD population (Figure 1).22 The commencement 
of dialysis does little to arrest the progression of heart failure and the prevalence rises 
up to 55% in end stage renal disease population (ESRD).22  
 
 
Fig 1.1: The figure shows the distribution of different CVD in CKD patients in the 
US Medicare (≥ 65years) population compared to general population. USRDS 
Annual Data Report 2012.22 CHF: congestive heart failure, AMI: acute myocardial infarction, 
CVA: cerebrovascular accident, TIA: transient ischaemic attack. 
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Table 1.4 Prevalence of CVD in different CKD stages 
CVD & CKD stages Prevalence (%) 
CHF  
Stages 1-2 26.8 
Stage 3 30.9 
Stages 4-5 40.9 
AMI  
Stages 1-2 9.7 
Stage 3 10.9 
Stages 4-5 12.9 
PVD  
Stages 1-2 24.1 
Stage 3 25.7 
Stages 4-5 29.6 
TIA/CVA  
Stages 1-2 18.1 
Stage 3 18.5 
Stages 4-5 20.2 
Distribution of different CVD in CKD patients in the US Medicare (≥ 65years) population. 
USRDS Annual Data Report 2012.22  
CHF: congestive heart failure, AMI: acute myocardial infarction, CVA: cerebrovascular accident, 
TIA: transient ischaemic attack. 
 
1.3.3 CVD mortality in CKD 
CKD is a state of very high mortality. The 5-year survival of men >64 years starting 
dialysis is worse than colon cancer or prostate cancer and the 5-year survival of 
women starting dialysis is worse than breast cancer or colon cancer.23 More than half 
the deaths in ESRD population are attributable to CVD. In a large population-based 
study evaluating the life expectancy of  over 1.5 million participants with varying 
levels of kidney function, it has been shown that the proportion of CVD deaths 
increase with increasing severity of CKD with 27.5% of CVD deaths in CKD 1&2 to 
58% CVD deaths in stage 5 and ESRD (Table 1.5). 24  
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Table 1.5 CKD stages and CVD mortality24 
CKD Stages CVD mortality (%) 
1 & 2 27.5 
3a 32.9 
3b 41.1 
4 48.8 
Stage 5 and ESRD 58.0 
 
1.3.4 Adverse effects of CKD on pre-existing heart disease 
In addition to the de novo heart disease in CKD, it is also important to understand the 
serious adverse effect CKD has on the outcomes of pre-existing heart disease. For 
example, in patients with acute myocardial infarction (MI), after adjustment for other 
risk factors, the risk of death or nonfatal cardiovascular complications increases 
significantly with declining GFR (hazard ratio 1.10 for each 10-unit decrease in GFR 
below 81.0 mL/min).25 
 The effect of renal dysfunction is even more pronounced on heart failure 
(HF) outcomes. Renal impairment is a common complication of patients with heart 
failure and a recent meta-analysis has shown that more than a quarter of patients with 
heart failure have moderate to severe renal impairment (eGFR<60mls/min) and the 
presence of renal impairment confers a serious adverse prognosis.26 The same study 
showed that mortality worsened incrementally across the range of renal dysfunction 
with 7% increased risk for every 10ml/min decrease in GFR. The renal impairment 
in heart failure is not merely a marker of HF severity but is shown to be an 
independent predictor of survival in HF patients. Hence, eGFR forms an important 
component of predictive models evaluating the mortality risk of HF patients wherein 
the impact of eGFR on survival is shown to be as significant as age and NYHA 
class.27 
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Summary of epidemiology: CKD is emerging to be an important public health 
problem and CKD patients suffer from very high cardiovascular morbidity and 
mortality. The next section discusses the risk factors that lead to cardiovascular 
disease in CKD.  
1.4 Pathogenesis of CVD in CKD 
The risk factors for CVD and CKD can be divided into traditional risk factors and 
non-traditional risk factors (Table 1.6). Traditional risk factors are those that are 
associated with increased CV risk in general population and non-traditional risk 
factors are specific to CKD or more common in CKD. The traditional risk factors 
such as hypertension, dyslipidaemia, diabetes, older age, etc. tend to be clustered in 
the CKD population and therefore the influence of individual risk factors in the 
pathogenesis of CVD is difficult to delineate.  
Table 1.6 Traditional and non-traditional risk factors of CVD in CKD 
Traditional risk factors Non-traditional factors 
Older age Albuminuria  
Male gender  Uraemic toxins (especially protein-bound 
toxins) 
Hypertension Anaemia 
Dyslipidaemia Abnormal calcium/phosphate metabolism 
including  
Diabetes mellitus Extracellular fluid volume over-load and 
electrolyte imbalance  
Smoking Inflammation  
Physical inactivity  Malnutrition 
Obesity Oxidative stress 
Family history of cardiovascular disease Sympathetic overactivity & Renin-
Angiotensin-Aldosterone-System (RAAS) 
activation 
 Fibroblast Growth Factor 23 (FGF23) 
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1.4.1 Traditional risk factors 
Dyslipidaemia: In CKD, the prevalence of dyslipidaemia is influenced by the level 
of GFR and the severity of proteinuria. Low GFR is associated with high serum 
triglycerides (TG) and low HDL cholesterol levels. As proteinuria worsens, total 
serum cholesterol, LDL cholesterol and TG levels all increase and HDL cholesterol 
levels decrease.28 Although there is high prevalence of dyslipidaemia in CKD, 
prospective data linking dyslipidaemia to CVD in CKD is limited. Most information 
is extrapolated from studies performed in the general population. Interestingly, 
however, a paradoxical relationship of low cholesterol with high mortality has been 
demonstrated in ESRD population.29 Moreover, large randomised controlled trials 
(RCTs) of lipid lowering therapy in ESRD have either failed show any survival 
benefit30,31 or at best shown only limited benefit.32 
Hypertension: The relationship between CKD and hypertension is bi-directional. 
Hypertension could be the cause of CKD in some instances and the effect of CKD in 
most situations. The presence and severity of hypertension in CKD can be influenced 
by several factors such as the etiology, duration and the severity of CKD. In a study 
of 1,795 patients with CKD, the prevalence of hypertension was shown to increase 
from 66% when the GFR was 83 ml/min to 95% when the GFR was12 ml/min.33 In 
both diabetic and non-diabetic CKD patients high systolic blood pressure is 
associated with high CVD risk 34 and blood pressure control appears to confer 
survival benefit.35 
Diabetes mellitus: DM is the most common cause of CKD in the developed world 
and is strongly associated with CVD.36 Although there is no randomized trial 
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evidence that demonstrates strict glycaemic control reduces CVD events, tight 
glycaemic control confers benefit by delaying the progression of kidney disease.37,38 
Obesity: In contrast to the general population, for which there is a U-shaped 
association between BMI and survival,39 in haemodialysis patients incrementally 
higher BMI is associated with better survival 40 Similar survival paradox is also seen 
in CKD patients not yet on dialysis. 41 
Smoking: As in the general population smoking has been shown to be associated 
with increased CVD risk in CKD.42 
As risk scores based on traditional risk factors were insufficient in capturing 
the extent of CVD in CKD43,44 and in view of the paradoxical association between 
some of the traditional risk factors and CV risk in CKD, there is growing interest in 
the non-traditional risk factors. 
1.4.2 Non-traditional risk factors 
The non-traditional risk factors of CVD include CKD-specific factors such as 
uraemic toxins, albuminuria, salt & water retention, CKD mineral bone disorder 
(CKD-MBD) and renal anaemia, and conditions common to most chronic illnesses 
such as malnutrition, inflammation and oxidative stress.45 Some of these factors are 
better studied than others and the ongoing research continues to add novel factors to 
this list. 
Anaemia: The prevalence of anaemia increases as kidney disease progresses and 
>50% of patients with a GFR less than 15ml/min have anaemia.46 Anaemia of CKD 
is associated with left ventricular hypertrophy (LVH), left ventricular systolic 
dysfunction and cardiovascular morbidity and mortality.47 48 49 Observational studies 
have found that for every 1g/dl decrease in haemoglobin (Hb) concentration, the 
combined risk of mortality, heart failure or developing LVH increases by 20–40% in 
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patients on chronic dialysis.50Although introduction of erythropoiesis stimulating 
agents (ESA) have improved the outcome of patients with advanced CKD, 
normalisation of Hb had not shown any benefits with regards to CV mortality.51,52 
Hence, most CKD guidelines recommend a Hb range of 10.5–12.5 g/dl for patients 
on ESA therapy. 
Albuminuria: Albuminuria is not only a marker of kidney damage but also a strong 
predictor of CVD morbidity and mortality. This association persists even in patients 
without diabetes or hypertension.53,54-56 The mechanism through which albuminuria 
exerts CV toxicity is not clearly understood. However, it is likely that albuminuria 
reflects endothelial damage. There is some evidence to show that therapies that 
reduce albuminuria (e.g. ACE inhibition) have beneficial effect on CVD morbidity 
and mortality in CKD.57 
CKD-Mineral Bone Disorder: As CKD progresses, serum calcium levels are 
reduced and parathyroid hormone (PTH) and inorganic phosphate levels are 
elevated.58 Several studies have demonstrated the association between raised 
phosphate, raised calcium and phosphate product and raised PTH and elevated CVD 
mortality.59-61 It is proposed that the toxicity is mediated through vascular 
calcification.62 Although no specific treatment strategy has benefit over the 
others,63,64 most CKD guidelines recommend controlling phosphate and PTH levels. 
Fibroblast growth factor 23 (FGF23), an endocrine hormone that regulates phosphate 
metabolism, has recently been identified as a novel risk factor associated with CVD 
in CKD. FGF 23 has been shown to induce LVH in animal models. Furthermore, 
elevated levels of FGF 23 is associated with LVH in CKD patients.65 
Salt & water retention: Chronic salt & water retention and overhydration are 
associated with poor CV outcomes in patients with CKD and ESRD.66,67 The adverse 
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effects are believed to be mediated through vascular stiffening and left ventricular 
hypertrophy (LVH). The effects of hemodynamic alterations in CKD on cardiac 
structure are discussed in detail under the heading LVH. 
Oxidative stress and inflammation: CKD is a state of high oxidative stress.68 
Oxidative stress is shown to cause vascular69 as well as myocardial70,71 damage and 
markers of oxidative stress are shown to be associated with left ventricular 
dilatation72 and impaired left ventricular ejection fraction in heart failure patients.73,74 
In CKD, markers of oxidative stress are predictive of mortality75 and clinical studies 
have demonstrated their association with atherosclerosis and vascular stiffening. 76,77 
CKD is a chronic inflammatory state, and inflammation becomes evident in 
the early stages of disease.20 Markers of inflammation such as C-reactive protein 
(CRP) and interleukin 6 (IL-6) are elevated in patients with CKD and are associated 
with CVD.78 However, benefits of anti-oxidant or anti-inflammatory therapy in 
reducing CV morbidity and mortality in CKD have not yet been shown. 
Renin-Angiotensin-Aldosterone-System (RAAS) activation: The activation of the 
RAAS occurs inevitably as kidney disease progresses. This has been demonstrated 
both in animal experiments79 and in humans.80 Kidney ischaemia is suspected to be 
the central mechanism.81 The deleterious effects of RAAS on the cardiovascular 
system have been well studied.82,83  The survival benefits of RAAS inhibition have 
also been shown in CKD.35 As a result, angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers are the mainstay of treatment of CKD. 
Sympathetic over-activity: CKD is associated with activation of the sympathetic 
nervous system.84 In a study of over 200 patients undergoing haemodialysis, it has 
been shown that increased sympathetic activity is independently predictive of 
cardiovascular morbidity and mortality. The study employed plasma noradrenalin 
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(NA) levels as a measure of sympathetic activity and showed that, for every 1 
nmol/L increase in plasma NA the risk of CV events increased by 8%.85 The strong 
association between sympathetic activity and left ventricular hypertrophy in this 
patient group has also been demonstrated.86 
Small RCTs have shown benefits of beta blockade in ESRD. Cice et al had 
shown, in a placebo-controlled RCT of 114 patients, that treatment with Carvedilol 
reduced CV mortality and hospital admission in ESRD patients.87 In a recent open-
label trial of 200 ESRD patients, Agarwal et al had shown that treatment with beta-
blocker was better in reducing CV mortality and hospitalisation for heart failure 
compared to ACE-I.88 However, beta-blockers still remain underused in this patient 
group.89 Large randomised trials are needed to evaluate the safety and efficacy of β-
blockers for the reduction of cardiovascular risk in patients with CKD. 
Uraemic toxins: There is growing interest in the role of uraemic retention solutes,90 
accumulating in the blood as a result of kidney failure, as mediators of 
cardiotoxicity.91 Uraemic retention solutes include: small water soluble compounds 
(MW< 500 Da) e.g. urea and creatinine that are removed by conventional dialysis; 
middle molecules (MW > 500 Da) e.g. β2-microglobin that are better cleared by high 
flux dialysers, and protein bound uraemic toxins (PBUT) e.g. the indole, indoxyl 
sulphate (IXS) and the phenol, p-cresyl sulphate (p-CS). As PBUTs are mostly 
bound to albumin, they are not well cleared by dialysis. Dialysis is able to clear only 
the free fraction but not the albumin bound fraction and therefore their serum levels 
of PBUTs continue to rise in patients.92  
It is becoming increasingly clear that PBUTs are associated with evolution of 
CVD in CKD, and IXS and p-CS are most highly implicated.91 Vasculotoxicity of 
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IXS has been demonstrated by its ability to cause endothelial dysfunction, vascular 
calcification and induction of oxidative stress.93-95 Vasculotoxicity of p-CS has also 
been shown.96,97  
Clinical studies have shown that IXS and p-CS are associated with vascular 
calcification and IXS is also associated with vascular stiffening. Furthermore, these 
toxins are also shown to predict cardiovascular and all-cause mortality.95,98 
Therefore, it is of interest to study the direct cardiac effects of these toxins in 
addition to their vasculopathic effects.  
In isolated cardiac tissue IXS caused fibrosis and hypertrophy in neonatal rat 
heart99 where inhibition of AMPK signalling was implicated.100 In adult rat hearts 
fibrosis and hypertrophy were linked to reactive O2 species (ROS) production and 
NFκB signalling.101 Reducing IXS levels by AST-120 (oral charcoal) reduced NFκB 
phosphorylation and fibrosis in 5/6 nephrectomy rats.102 Fibrosis would be expected 
to hinder electrical conduction and predispose to arrhythmias. Although the above 
studies demonstrated the role of PBUTs in inducing cardiac ultrastructural changes, 
studies on the effects of these toxins on the mechanical and electrical properties of 
cardiomyocytes are still lacking. 
Summary 
In summary, the uraemic milieu comprises a unique set of factors with the potential 
to cause both vasculopathy and cardiomyopathy. In the next section I describe the 
structural and functional changes that the heart undergoes in the uraemic 
environment. 
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1.5 Pathology and Pathophysiology 
1.5.1 Uraemic Vasculopathy 
Although the focus of the thesis is Type 4 CRS i.e. the cardiac disease of CKD, it is 
essential to understand the vasculopathic effects of CKD as CKD patients are at a 
higher risk of coronary artery disease (CAD). Indeed, CKD is considered as a 
coronary artery disease risk equivalent i.e. CKD patients without known coronary 
heart disease (CHD) have a risk of subsequent cardiovascular events that is 
equivalent to that of patients with established coronary disease.103 The first evidence 
of the unique characteristics of coronary artery disease in CKD was shown by 
Schwarz et.al. in 2000. 104 In this study, post mortem samples of coronary arteries 
from patients with end stage renal disease were analysed and compared with those of 
non-renal patients with CAD. It was found that coronary plaques in ESRD patients 
were characterised by increased media thickness and marked calcification. In 
addition, Nakano and colleagues demonstrated similar calcification of CAD in pre 
dialysis CKD patients. This study also showed that the frequency of calcified CAD 
lesions increased with falling renal function.105  
Arterial calcification occurs in the tunica intima or tunica media of the vessel 
wall. Intimal calcifications are calcium deposits on atherosclerotic lesions and medial 
calcification occurs as a result of osteoblast transformation of medial smooth muscle 
cells.106 The altered calcium, phosphate and PTH homeostasis that occurs in CKD 
appears to play a major role in the evolution of uraemic vasculopathy. Moreover, low 
levels of inhibitors of calcification (e.g. fetuin-A) also contribute to arterial 
calcification.106 Clinically, detection of arterial calcification in vivo is undertaken by 
plain x-rays, CT scans and advanced tools such as electron beam CT and multi slice 
CT.106 The presence of arterial calcification is a strong predictor of CV and all-cause 
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mortality in patients with CKD. The association has been found to be independent of 
traditional atherogenic factors.107  
In addition to arterial calcification, arterial stiffening is also found to be 
highly prevalent in CKD.62 Arterial stiffness is evaluated by measuring pulse wave 
velocity (PWV).108  Traditional risk factors such as age and diabetes, and CKD 
related factors such as albuminuria and vascular calcification have been found to be 
associated with arterial stiffening.109, 108 The clinical relevance of arterial stiffness in 
CKD was shown in a study of 241 ESRD patients with a median follow up of 72 
months. The study showed that for each 1m/sec increase in PWV the relative risk of 
all-cause mortality was 1.39. 110  Increase in arterial stiffness is suspected to increase 
cardiac workload and shear stress of downstream vasculature leading to poor CV 
outcomes.107 
As vascular calcification and stiffness are highly prevalent in CKD and are 
predictive of mortality they were utilised as surrogate end points in studies aimed at 
prevention of CVD in CKD. For example, in an RCT of 360 ESRD patients, 
cinacalcet, a treatment for secondary hyperparathyroidism, was shown to reduce 
vascular calcification.111 However, a recent large RCT of over 3800 CKD patients 
with moderate to severe secondary hyperparathyroidism, showed that treatment with 
cinacalcet conferred no benefits in terms of cardiovascular mortality.112  
These series of negative trials in CKD, using conventional and novel 
therapies for vasculopathy that failed to offer survival benefit highlights the 
complexity of CVD in CKD, and emphasises the importance of improving our 
understanding of the cardiomyopathic aspect of cardio-renal interaction.  
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1.5.2 Uraemic Cardiomyopathy 
A brief description of cardiac hypertrophy in general and the associated 
pathophysiology is presented here before discussing uraemia-specific myocardial 
abnormalities. 
The weight of human heart increases from 20 g at birth to nearly 350 g at 
adulthood.113 Further increase in heart weight can occur due to extrinsic stimuli such 
as increased work load, RAAS activation, cytokines, etc or intrinsic genetic 
abnormalities.114  This is called as cardiac hypertrophy. Although the term 
‘hypertrophy’ refers to increase in the volume of tissues due to increase in cell size, 
cardiac hypertrophy in most situations involves both increase in cardiomyocyte size 
and number, and increase in the number of connective tissue cells i.e. hyperplasia.  
The cardiac hypertrophy can be associated with improved cardiac function and 
energy use when it is referred as ‘physiological’ hypertrophy or impaired cardiac 
function and energy use when it is called as ‘pathological hypertrophy’.115 Another 
important characteristic of physiological hypertrophy is the reversibility.116 Physical 
exercise and pregnancy are examples where physiological hypertrophy occurs 
whereas hypertension and aortic stenosis are situations where pathological 
hypertrophy occurs.114 It has been shown that in pathological hypertrophy the 
ultrastructural composition of the myocardium is altered with disproportionate 
increase in fibrous tissue. A study on human autopsy samples of pressure overload 
induced left ventricular hypertrophy (LVH) showed that the myocyte volume 
increased by 65% whereas the connective tissue cell numbers increased by 141%. 
There was an overall decrease in volume percentage of myocytes by 6%.113  Such 
changes have direct consequence on cardiac function by impairing the ability of 
myocardium to contract (inotropy) and its ability to relax (lusitropy).117 Furthermore, 
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the mediators of pathological hypertrophy also cause cellular and molecular 
abnormalities such as altered expression and function of contractile proteins, altered 
energy metabolism, abnormalities in excitation-contraction coupling, etc. leading to 
progressive myocardial dysfunction and heart failure.118 
 There are several different imaging modalities available to assess cardiac 
structure and function. The most commonly employed tool is echocardiogram (echo). 
Echo can help evaluate systolic and diastolic function, and estimate left ventricular 
mass. The widespread availability, portability and negligible risk are the advantages 
of echocardiogram. The following are the other imaging modalities that are used in 
special circumstances: 
• Cardiac magnetic resonance (CMR) is more accurate and reproducible 
compared to echo. In addition to assessing cardiac structure and function 
CMR can also provide information on perfusion and fibrosis of the 
myocardium.119 
• Radionuclide ventriculography (RVG), that involves exposure to ionizing 
radiation, can be used when there is significant wall motion abnormality or 
distorted geometry.120 
• Cardiac CT helps in the evaluation of coronary arteries and characterization 
of myocardium in addition to assessment of cardiac function.121 
• Single photon emission computed tomography (SPECT) is employed to 
assess myocardial perfusion in addition to cardiac function.122 
  
37 
 
 
1.5.2.1 Pathology 
Ultrastructural changes  
A study of post mortem examination of heart from dialysis patients provided the first 
glimpse of the ultrastructural changes of the uraemic heart.123 The study showed that 
uraemia is associated with hypertrophy of cardiomyocytes and there is evidence of 
interstitial fibrosis. For comparison, the study analysed hearts from hypertensive 
patients and non-hypertensive control patients. The most significant finding of the 
study was that there is reduction in capillary length density in uraemic heart i.e. the 
capillary growth does not keep pace with the growth of myocardium and interstitium. 
This architectural abnormality has the potential to render the cardiomyocytes 
relatively hypoxic at times of increased demand. The authors suggested that 
activation of renin-angiotensin system and sympathetic overactivity could be 
potential mechanisms.  
 A recent study using isolated neonatal rat cardiomyocytes and fibroblasts 
demonstrated that indoxyl sulphate, a protein bound uraemic toxin, exhibited pro-
fibrotic, pro-hypertrophic and pro-inflammatory properties after incubation for 48 
hours in the cell culture.99 This offers an additional mechanism of adverse cardiac 
remodelling in CKD in addition to the effects of RAAS activation and sympathetic 
stimulation. 
Morphological changes  
The most commonly employed tool for studying cardiac structural abnormality in 
CKD patients is echocardiography (echo). There had been several such studies and 
the most common finding is left ventricular hypertrophy (LVH).  
The first of such studies was published in 1995.124 In a prospective study of 
over 400 patients starting dialysis, Foley et.al. showed that 73.9% of the patients had 
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LVH at the time of starting dialysis. Left ventricular dilatation (LV cavity volume 
>90ml/m2) was seen in 35.5% of patients. Only 15% of the patients had an 
echocardiographically normal heart. Age, male gender, arterial pulse pressure, blood 
urea level and serum albumin were found to be independently associated with LVH. 
Moreover, LVH was found to be independently predictive of mortality in these 
patients. It was also shown that the median time of development of heart failure in 
patients with LVH was 38 months.125 Later studies have demonstrated the 
association between anaemia and LVH in CKD.125 
The most recent study evaluating cardiac structure and function of over 3000 
CKD patients established that LVH is the predominant structural abnormality of the 
heart.126 The study showed that the prevalence of LVH increased with increasing 
severity of CKD. The prevalence was 32%, 48%, 57%, and 75% for eGFR categories 
>60, 45–59, 30–44, and <30 ml/min respectively. The severity of LVH, as measured 
by LV mass, was 46.1, 50, 52.5 and 57.8g/m2.7 respectively. The relationship 
persisted even after adjusting for hypertension. 
In addition to neurohumoral and toxin related mechanisms involved in LVH 
and fibrosis in CKD, preload and afterload related factors also play a role. The 
afterload-related factors include systemic arterial resistance, elevated BP, and 
impaired aortic compliance. 127,128 The last factor could be related in part to the aortic 
calcification and aortic stiffness seen in CKD and ESRD. These afterload-related 
factors result in myocardial cell thickening and on echocardiogram a concentric LV 
remodelling. Preload-related factors include expansion of intravascular volume (salt 
and fluid retention), anaemia, and, in certain circumstances, large flow arterio-
venous fistulas placed for vascular access for haemodialysis.129-131 These factors 
result in myocardial cell lengthening and on echocardiogram an eccentric or 
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asymmetric LV remodelling. Both afterload- and preload-related factors may operate 
simultaneously and probably have additive or even synergistic effects. Therefore, it 
is not easy to separate the effects of preload and afterload factors in the pathogenesis 
of LVH.  
Cardiac MRI has also been employed to characterise the structural 
abnormality of uraemic cardiomyopathy (UCM). In a study of 134 dialysis patients 
using Gadolinium enhanced cardiac MRI, Mark et.al. had shown that LV mass is 
correlated with diffuse myocardial fibrosis.132 The diffuse pattern of myocardial 
fibrosis was found to be unique to UCM, different from the sub-endocardial fibrosis 
associated with ischaemic heart disease. 
As advanced CKD and ESRD is in most cases irreversible, LV mass may not 
be normalised in these subjects. However, appropriate fluid and blood pressure 
control and anaemia treatment results in some degree of reversal of LVH.133 It has 
also been shown that in experimental uraemia and in a small observational study, 
reduction in circulating indoxyl sulphate, a non-dialysable toxin, was associated with 
some reduction in LV fibrosis and LV mass respectively.132,134 
In summary, the predominant structural abnormality of UCM is LVH. From 
the available evidence, it is clear that LVH of UCM is characterised not only by 
cardiomyocyte hypertrophy but also by diffuse fibrosis suggesting a pathological 
remodelling. As heart failure is the predominant cardiac abnormality of CKD and 
LVH in CKD is a strong predictor of future heart failure, it is of vital importance to 
understand the functional consequences of this potentially pathological cardiac 
remodelling.  
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1.5.2.2 Pathophysiology 
Cardiomyocyte pathophysiology (cellular level) 
The heart is a transducer that converts chemical energy from nutrients into 
mechanical energy in the form of contractions. Cardiomyocytes are the functional 
units of the heart. The individual components of this transduction process such as 
substrate utilisation, energy production and generation of contractions have been 
studied in the uraemic milieu providing some useful insights into the working of 
uraemic heart. 
Substrate utilisation: The altered architecture of the uraemic heart with its interstitial 
fibrosis and myocyte-capillary mismatch renders the environment of cardiomyocytes 
oxygen-poor.  In such a setting the metabolism shifts from fatty acid utilisation to 
anaerobic glucose utilisation.135 The inverse relationship between myocardial 
glucose utilisation and eGFR has been shown recently. It has also been shown that 
alteration in fatty acid utilisation has strong association with mortality in ESRD 
patients. 136 
Energy production: In 1993 Raine et al had shown, with the help of NMR 
spectroscopy, the effects of uraemia on cardiac energy synthesis in a uraemic rat 
model.137 The study showed that, in rats rendered uraemic by 5/6th nephrectomy, the 
myocardial phosphocreatinine content was markedly reduced and there was also 
reduction in phosphocreatinine/ATP ratio. Similar changes were also shown in 
ESRD patients using NMR spectroscopy implying impaired energy synthesis in 
uraemia.138 
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Cardiomyocyte contractility: Two studies have shown the effects of uraemia on 
cardiomyocyte contractile function in the uraemic rat model. Both demonstrated that 
uraemia impairs contractile function of cardiomyocytes. There is impairment in 
myocyte calcium handling and as a result impaired relaxation. It was also 
demonstrated that the changes are independent of blood pressure. The authors 
proposed that these changes might translate as diastolic dysfunction in vivo.139,140 
Cardiac pathophysiology (organ level) 
As well as its use in cardiac structure, the most commonly employed tool for 
assessment of cardiac function in CKD is echocardiography (echo). The studies 
evaluating cardiac function in CKD included both ESRD (receiving renal 
replacement therapy) and pre-dialysis CKD patients. The impact of uraemia on both 
systolic and diastolic function was evaluated. The studies provided useful 
information on the extent of cardiac dysfunction in CKD and its significance on 
patient survival in CKD. A brief summary of some of the studies is presented here. 
Systolic dysfunction: The analysis of systolic function by echocardiogram is usually 
performed by methods evaluating ejection phase, in particular ejection fraction. The 
first such evaluations were carried out nearly 2 decades ago. Early studies focussed 
mainly on advanced CKD and ESRD. A prospective study 432 patients starting 
dialysis showed 16% of the patients had systolic dysfunction (ejection fraction 
<50%) at the time of commencement of dialysis. 125 In the study, the median survival 
of patients with systolic dysfunction on starting dialysis was 38 months, with an odds 
ratio for mortality, compared to those with normal echocardiogram, of 1.88 
(independent of age, gender, diabetes, and ischemic heart disease). In the most recent 
prospective study of advanced CKD patients followed through to dialysis, the 
ejection fraction was found to decline during the transition from CKD not requiring 
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dialysis to the dialysis-dependent stage. Moreover, the prevalence of systolic 
dysfunction (EF<50%) increased form 29% in the pre-dialysis stage to 48% in the 
dialysis stage.141 
Diastolic dysfunction: Early studies evaluating diastolic dysfunction employed 
transmitral flow assessments.142 As transmitral flow is considered load-dependant,143 
in recent years tissue Doppler imaging (TDI) of the mitral annulus or myocardial 
walls was introduced in the evaluation of segmental and global diastolic function.144 
Small observational studies have demonstrated the high prevalence of diastolic 
dysfunction in CKD and its association with mortality.145,146 
Although the above studies demonstrated the existence of systolic and 
diastolic dysfunction in CKD, it is important to note that such studies included 
patients with concomitant cardiovascular diseases or risk factors of cardiovascular 
diseases such as diabetes. Moreover, the studies lacked sufficient power to control 
for such confounders. Therefore, it was difficult to delineate the effects of CKD per 
se on cardiac function. A recently published large population based study of over 
3000 CKD patients tried to address such issues.126 The study evaluated cardiac 
structure and function using echo in asymptomatic CKD patients of varying severity. 
The study demonstrated that LVH is the predominant structural abnormality of CKD 
and its prevalence and severity increased with increasing severity of CKD. With 
regards to cardiac dysfunction, systolic dysfunction was demonstrable only in 8% of 
the patients and there was no association between kidney function and systolic 
dysfunction. The study showed a large prevalence of diastolic dysfunction with only 
29% of the cohort having normal diastolic function. The majority of the patients had 
mildly abnormal diastolic relaxation (62%), with a minority categorized as 
43 
 
 
moderately (8%) or severely abnormal (1%). However, there was no association 
demonstrable between kidney function and diastolic dysfunction. The authors 
concede that there was a high prevalence of mild dysfunction in all stages of CKD 
and hence they could not demonstrate a graded relationship between renal 
dysfunction and diastolic dysfunction. 
Echocardiographic studies of UCM have helped establish LVH as the 
predominant structural characteristic of UCM with strong dose-response relationship 
with severity of uraemia. However, its corresponding functional correlate was not 
identifiable using resting echocardiographic assessments. Therefore, there remains an 
important unanswered question as to whether the cardiac remodelling in CKD is an 
adaptive physiological response that compensates for the altered haemodynamic 
conditions and chronic hypertension in CKD or a maladaptive pathology secondary 
to a cardiotoxic uraemic milieu. The important discriminatory feature between these 
two states would be the cardiac function. An adaptive cardiac remodelling would 
result in normal or supra-normal cardiac function whereas a maladaptive remodelling 
would result in impaired cardiac function.115 As the parameters of resting cardiac 
function in CKD were poorly discriminatory in this regard, it would seem an 
alternative approach is needed. 
 1.6 The concept of cardiac power output 
“A heart is what a heart can do”. 
  - Sir James MacKenzie (1853-1925) 
The heart is a pump that imparts hydraulic energy into the arterial system to maintain 
the circulation of blood. Without this energy the circulation would come to a 
standstill. In physics, energy per unit time is ‘power’ and hence the rate at which the 
heart imparts hydraulic energy onto blood circulation is the ‘cardiac power output’ 
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(CPO). If one can quantify the power output of the heart one gets a direct indicator of 
cardiac performance. CPO can be measured in watts as a product of the heart’s flow 
output and arterial pressure. CPO measurements can be instantaneous measurements 
or steady state measurements. The former has been attempted in earlier studies using 
sophisticated, invasive techniques measuring cardiac power at a particular time point 
of cardiac cycle. 147,148 However, a more clinically applicable measurement is the 
average steady state measurement by utilising the steady component of the flow, the 
cardiac output (CO) and that of pressure, the mean arterial pressure (MAP).149  
COxMAPCPO =  
Such a fundamental measurement of cardiac performance allows us to 
delineate another important property of the heart, its reserve function. The heart does 
not function at a fixed power output. It can increase its performance at times of 
demand and each heart has a ceiling maximum power output (CPOmax) that is 
physiologically achievable. The difference between the resting performance and the 
peak performance of the heart is the cardiac functional reserve.  
Cardiac Functional Reserve = CPOmax - CPOrest 
When a heart begins to fail, compensatory mechanisms will be activated in 
order to maintain the resting cardiac performance within as normal a range as 
possible. Its peak performance will be, however, compromised and diminished. It is 
this diminution of the cardiac reserve that represents the true pump dysfunction and 
needs to be measured to enable us to detect early cardiac dysfunction in CKD before 
the patient becomes symptomatic and also understand whether cardiac responses to 
uraemia are adaptive or maladaptive.150  
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1.6.1 Measuring CPO 
The essential step in the measurement of CPO is measuring cardiac output. Cardiac 
output can be measured invasively or non-invasively. The invasive methods include 
the direct Fick method described by Adolph Fick in 1870151  and the thermodilution 
technique described by Swan and Ganz in 1970.152  
Direct Fick method: This method is based on the principle that we can calculate the 
blood flow through the lungs (and in turn the cardiac output), if we know the amount 
of oxygen uptake by the lung and the arterio-venous oxygen difference, using the 
following equation. This method involves right heart catheterisation for sampling 
mixed venous blood and peripheral arterial cannulation for sampling arterial blood. 
 
Where 
Cardiac output (Qt) is pulmonary blood flow in litres/minute 
VO2 is oxygen uptake in litres/minute 
CvO2 is the venous concentration of oxygen   
CaO2 is the arterial concentration of oxygen 
Thermodilution technique: It is a form of indicator-dilution technique that involves 
right heart catheterisation, wherein the indicator is a small known volume of either 
dextrose or saline that is cooler than blood. It is injected as a bolus through the 
proximal port of the pulmonary artery catheter, where it mixes with blood in the right 
ventricle. The mixing lowers the temperature of intraventricular blood. As the blood 
flows past the distal thermistor port, the thermistor records the temperature change 
over time and can electronically display a temperature-time curve. The area under 
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this curve is inversely proportional to the flow rate in the pulmonary artery. This 
flow rate should be equal to cardiac output, assuming that there is no intracardiac 
shunt. 
In both the above techniques a pharmacological stimulus such as dobutamine 
is employed to measure peak cardiac output.  
Non-invasive measurement of cardiac output: Non-invasive techniques of 
measuring cardiac output include CO2 rebreathing technique and foreign gas 
rebreathing technique. Physical exercise, using a treadmill or bicycle ergometer is 
used to stimulate the heart to measure peak cardiac output. 
CO2 rebreathing technique: This technique is discussed in detail in the methodology 
section. Briefly, an indirect Fick method is used in which blood concentrations of 
CO2 in mixed venous and arterial blood are estimated indirectly from their partial 
pressure in the gas phase, with CO2 as the indicator gas, to determine cardiac output. 
Two approaches have been used for the measurement of mixed venous PCO2 during 
exercise: Rebreathing from a rubber bag that contains a low concentration of CO2, 
and the equilibration method, which uses a bag that contains a high concentration of 
CO2 in oxygen. The mixed venous CO2 content is determined from the CO2 tension, 
which can be estimated from the CO2 tension curve as it gradually increases toward a 
limit during rebreathing of a known gas mixture (e.g., 5% CO2 and 95% O2). End-
tidal CO2 is taken as a measure of CO2 partial pressure in alveolar gas and is 
representative of arterial blood CO2. Carbon dioxide output is determined from the 
expired air sample. 
Inert gas rebreathing technique: In this method, a soluble inspired gas such as 
acetylene or nitrous oxide is used for rebreathing. The mixed venous content of the 
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inert gas is taken as zero, and arterial partial pressure is assumed to be the same as in 
end-tidal air. The application of such methods that uses the inert gas rebreathing 
technique during exercise has been described in patients with heart failure.153 
1.6.2 Clinical utility of CPO 
Measured invasively or non-invasively the peak cardiac power output (CPOmax) 
appears to be a direct indicator of cardiac function and the best predictor of survival 
in patients with a failing heart. It has been shown that peak cardiac power output 
measured using dobutamine challenge was better at predicting survival in heart 
failure patients compared to resting haemodynamic indices.149 Later in 2001 Tan 
et.al had shown that CPOmax measured non-invasively, using CO2 rebreathing 
technique, during cardiopulmonary exercise test (CPX), is the best predictor of 
survival in patients with heart failure compared to conventional indices.154 The 
results have been reproduced in a later study using inert gas rebreathing technique.153  
 The major advantage of measuring peak performance of the heart is its 
ability to discriminate between health and disease states and stratification of severity 
of disease states. As shown in the following schematic diagram, in failing hearts, the 
resting performance of the heart is kept as normal as possible by compensatory 
mechanisms whereas the peak performance falls in proportion to the severity of 
underlying disease (Figure 2). Moreover, CPO serves as an overall index of cardiac 
performance by incorporating both volume generating capacity and the pressure 
generating capacity of the heart. In situations where resting cardiac assessments 
failed to delineate the pathophysiology, assessment of peak cardiac performance 
would serve as an alternative. 
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Fig 1.2: Schematic diagram depicting cardiac functional reserve of healthy heart in comparison with a spectrum of failing hearts. It demonstrates 
that the baseline performance of the heart is not as good as the peak performance in discriminating health and disease states.150
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1.6.3 Assessment of peak cardiac performance in CKD 
There have been few attempts at evaluating stress cardiac function in CKD. A study 
measuring myocardial contractile reserve in paediatric CKD patients, using exercise 
echocardiography, had shown that the contractile reserve is impaired even when 
resting parameters of cardiac function are normal.155 In another study of paediatric 
CKD patients, peak oxygen consumption (VO2max), a measure of physical functional 
reserve and a surrogate for peak cardiac performance, is shown to be impaired 
compared to healthy controls.156 Since these paediatric populations are assumed to 
have minimal atherosclerosis, the findings suggest that CKD per se may have direct 
deleterious effects upon cardiac function. However, adult CKD patients without CV 
comorbidities have not yet been studied. Therefore, studies specifically designed to 
evaluate cardiac reserve in adult CKD patients without co-morbid atherosclerosis 
substrates are needed to obtain useful insights into uraemic cardiomyopathy. Studies 
measuring exercise capacity of adult patients with CKD and ESRD patients provide 
some useful insights. 
1.6.4 CPX studies in CKD 
CPX studies in CKD and ESRD patients have shown impaired physical functional 
reserve and a negative survival impact.157,158 However, these studies did not exclude 
patients with IHD, diabetes mellitus or pre-existing HF and therefore it is difficult to 
ascertain whether the observations were primarily due to CKD or secondary to 
cardiovascular diseases. Moreover, there are several other factors that limit the utility 
of measures of exercise capacity such as VO2max or anaerobic threshold (AT) in 
assessing peak cardiac performance in CKD.  
The question one needs to ask is ‘what do we measure when we measure exercise 
capacity in CKD patients?’ The claim that measures of exercise capacity could serve 
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as a surrogate of cardiac reserve function in CKD needs verification. The claim is 
based on the premise that VO2 is a product of cardiac output (CO) and arterio-venous 
difference in oxygen concentration [VO2= CO x C(a-v)O2] and hence VO2 could 
serve as a surrogate of cardiac output. There are several physiological considerations, 
commonly described in textbooks of exercise physiology,151 which would render this 
simplified model less applicable in CKD. 
• Anaemia: Oxygen is primarily transported as oxyhaemoglobin (and a small 
fraction dissolved in plasma) and it has been estimated that the O2 carrying 
capacity of the blood falls from 22.5 ml/dL to 14.1 ml/dL as the haemoglobin 
concentration drops from 16 g/dL to 10 g/dL.151 Hence, for a given cardiac 
output, the impaired O2 delivery to exercising skeletal muscles, due to lower 
Hb, results in reduced peak VO2 and anaerobic threshold (AT).  
• Chronic metabolic acidosis: Exercising skeletal muscles generate acidic end 
products and the ventilation must keep in pace with the acid load to maintain 
normal pH. The presence of metabolic acidosis in CKD would add to the acid 
load and limit exercise capacity because of higher ventilatory requirements. 
• Peripheral vascular disease: PVD is a common co-morbidity of CKD. The 
diseased vasculature with reduced internal diameter impairs blood flow to the 
exercising skeletal muscles. The relative ischaemia leads to early onset of 
lactic acid production and reduced AT irrespective of normal cardiac 
performance.151 
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• Skeletal myopathy: Muscle wasting is not an uncommon finding in ESRD. 
Reduced skeletal muscle mass limits the utilisation of delivered O2. This 
coupled with the less studied phenomenon of skeletal myopathy secondary to 
uraemia would limit exercise capacity in spite of a normal cardiac output.159 
It has indeed been shown that haemoglobin, serum albumin, co-morbid diabetes 
mellitus and cardiovascular disease are significant determinants of exercise capacity 
in dialysis patients.160 Therefore this raises the possibility that exercise capacity in 
CKD is just a composite marker of co-morbidities rather than a true representation of 
cardiac performance. However, better interpretation of conventional CPX parameters 
in CKD can be achieved by employing techniques that simultaneously measure 
direct indicators of cardiac performance as well as exercise capacity.161 
1.6.5 Measuring CPOmax and cardiac functional reserve in CKD 
The deleterious effects of the uraemic milieu on the heart, as discussed above, 
provides the physiological basis for the hypothesis that CKD per se would cause 
impairment of cardiac functional reserve. Furthermore, it is highly pertinent to note 
that CKD is associated with very high mortality in situations of high cardiac demand. 
The annual mortality secondary to sepsis is 30 to 45 fold higher in dialysis patients 
when compared to general population,162 the one year post-MI mortality is more than 
50% in dialysis patients163 and CKD is also shown to have an adverse effect on 
survival during surgery.164 Thus, on the one hand we have a set of mechanisms in 
CKD that could potentially cause impaired cardiac reserve and on the other hand we 
have evidence of the consequence of such impaired cardiac reserve in CKD. 
However, no evidence is hitherto available to measure and demonstrate diminished 
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cardiac functional reserve in CKD and this thesis discusses the first such evaluation 
of peak cardiac power and cardiac functional reserve in this patient group.  
In this thesis, therefore, I defend the following hypotheses.  
1.7 Hypotheses 
The hypotheses to be tested in this thesis are as follows. 
Study 1  
• Hypothesis: Peak cardiac power and cardiac functional reserve are impaired 
in asymptomatic chronic kidney disease patients in the absence of any known 
cardiac diseases or diabetes mellitus. 
• Aim: To measure peak cardiac power and cardiac functional reserve as a 
direct indicator of cardiac dysfunction in asymptomatic patients with diverse 
severity of CKD. 
Study 2 
• Hypothesis: Renal transplantation improves peak cardiac power in chronic 
kidney disease. 
• Aim: To measure peak cardiac power in patients receiving kidney 
transplantation, before and after transplant surgery. 
Study 3 
• Hypothesis: Cardiac structure is altered in asymptomatic chronic kidney 
disease patients in the absences of any known cardiac disease or diabetes 
mellitus.  
• Aim: To examine the relationship between echocardiographic measures of 
cardiac structure and the severity of renal dysfunction.  
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Study 4 
• Hypothesis: Serum protein-bound uraemic toxins are inversely related to 
peak cardiac power in chronic kidney disease. 
• Aim: To evaluate the association between serum levels of protein bound 
uraemic toxins and peak cardiac power in CKD. 
Study 5 
• Hypothesis: Indoxyl sulphate has direct inhibitory effect on mechanical 
properties of isolated rodent cardiomyocytes. 
• Aim: To evaluate the physiological effects of indoxyl sulphate, a protein-
bound uraemic toxin on the mechanical properties of isolated 
cardiomyocytes. 
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CHAPTER 2 
 
Methodology 
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METHODS 
 
The overall aim of this study was to investigate the effects of chronic kidney disease 
on cardiac function. This chapter describes the common methodology relevant to the 
whole project and specific information is presented in the individual chapters. 
2.1 Study design 
In vivo study  
Cross-sectional study comparing cardiac function of patients with increasing severity 
of CKD and varying levels of the candidate biomarkers to a reference group of 
healthy volunteers as controls. Data from heart failure patients of New York Heart 
Association (NYHA) class II & III were used as positive controls. 
• The CKD group (n=70): The group consisted of patients in CKD stage 2 to 
stage 5 (pre-dialysis).  
• Healthy volunteers (n=101): Existing database of healthy volunteers was 
utilised for analysis.  
• Heart failure patients (n=39): Historical data from the center were used for 
comparative analysis. 
Longitudinal study: A subgroup of CKD subjects who underwent kidney 
transplantation during the study period underwent a repeat CPX study post-
transplantation to assess the effects of kidney transplantation on cardiac function. 
In vitro study 
The acute physiological effects of the uraemic toxin indoxyl sulphate (IXS) was 
tested on freshly isolated rodent cardiomyocytes. 
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2.2 Setting 
The in vivo study was conducted at the Yorkshire Heart Centre, Leeds Teaching 
Hospitals NHS Trust, Leeds, UK.  
The in vitro experiments were conducted in the Faculty of Biological Sciences in 
University of Leeds, Leeds, UK.  
2.3 Ethics approval 
Ethical approval was obtained from South Yorkshire research ethics committee for 
all experiments (Ref: 11/H1310/8). All subjects received verbal and written 
explanation of the procedures involved and completed and signed consent forms.  
2.4 Recruitment  
Patients with CKD stages 2 to 5 were identified by a search of the renal database in 
Leeds Teaching Hospitals NHS Trust. Eligible subjects were approached in the 
outpatient clinics. Patient information sheets were provided and written consent 
obtained according to ICH GCP recommendations before participation. A total of 70 
CKD patients were recruited for the study. The patients were recruited over a period 
of 3 years from a population of >1500 CKD patients under follow up in renal clinics. 
Sampling was determined only by the following inclusion and exclusion criteria and 
the willingness of potential participants to take part. Only patients able to understand 
spoken/written English sufficiently to provide signed informed consent to take part 
in clinical study were recruited. Exclusion criteria included patients unable or contra-
indicated to perform exercise on a treadmill; patients whose exercise ability was 
limited by known significant musculoskeletal, cardiovascular, pulmonary, hepatic, 
neurological or other non-renal medical disorders. As per study design, to improve 
on previous protocols and exclude those with potential confounding factors 
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contributing to cardiac dysfunction, patients with any known cardiovascular diseases 
such as ischaemic heart disease, arrhythmia, valvular heart disease, peripheral 
vascular disease, cerebrovascular disease and renovasular disease, and diabetes 
mellitus were excluded. 
2.5 Investigations 
Baseline Characteristics: The age, ethnicity and cause and level of CKD/eGFR were 
recorded.  Baseline cardiac assessment was performed in Renal and Cardiac 
outpatients and non-invasive investigation departments in Leeds Teaching Hospitals. 
This consisted of previous cardiac history, clinical examination, electrocardiogram, 
echocardiogram, biomarker assay and cardiopulmonary exercise testing (CPX). The 
cardiac history included any cardiac events or interventions, risk factors for 
cardiovascular disease and relevant medications. The clinical examination included 
formal cardiac and respiratory system examination, assessment of volume status and 
body mass index. 
Investigations: Information gained from standard investigations as part of good NHS 
clinical practice were recorded and not duplicated, such as routine full blood counts 
(FBC’s), urea and electrolytes (U&E’s) and estimated GFR measurements based on 
MDRD formula,11 and other blood tests according to the individual patients’ clinical 
needs (e.g. glucose, HbA1C, cholesterol, Ca++, phosphate, etc) and standard 12-lead 
ECG. 
Apart from the above clinically indicated tests, the project-specific investigations for 
this study include the following: - 
1. Cardiopulmonary exercise test (CPX) 
2. Echocardiogram 
3. Biomarker assays 
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2.5.1 Investigation 1: Cardiopulmonary exercise testing 
Laboratory Conditions 
All testing was performed in a dedicated cardiac power output laboratory in the Non-
Invasive Unit of Cardiology, Leeds General Infirmary.  The ambient temperature 
was maintained at 21⁰C and the room was well-ventilated.   
Subject Preparation 
Prior to attending the laboratory for exercise testing, all subjects abstained from food 
and caffeine (3 hours) and alcohol (12 hours) to ensure that heart rate, blood pressure 
and flow measurements were undertaken without the influence of stimulants. Also, 
an exercise free period of 24 hours was required before each session to ensure a fully 
rested state, and hence maximal voluntary effort, on each treadmill test. During the 
visit to the laboratory, all volunteers underwent familiarisation with the equipment 
(treadmill, facial gas collection apparatus, gas cylinder contents for CO2 rebreathing 
manoeuvres and CPX machine function). Any individual who had never used a 
treadmill was given instruction as to how best to walk without difficulty or placing 
undue strain on themselves. All procedures were described in detail, followed by 
discussion of any of the subject’s queries or concerns. Any subject wanting to 
withdraw from the project was given the opportunity to do so before commencement 
of the tests or via the subject’s voluntary termination during the test.  
Any subject that did not complete the exercise test to maximal volitional 
effort was withdrawn from the data set. One of the participants was unable to walk 
on the treadmill and another participant developed ST-T changes during the CPX 
which was later investigated and found to be non-specific. Both the participants were 
withdrawn from the study. 
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CPX gas analysis system 
Breath-by-breath gas analysis and measurements of cardiac output were performed 
using the automated Medgraphics Ultima system (Medgraphics Corporation, St. 
Paul, Minnesota, USA). This is a diagnostic exercise testing system that integrates 
both gas analyser and 12-lead ECG. Respiratory data were analysed and presented 
using Breeze Suite (version 5) and the ECG recording via Q-Stress Exercise ECG 
Testing System (Quinton Cardiology Systems, Inc.). 
The Medgraphics gas analyser consists of a zirconia fuel cell that measures 
oxygen and an infra-red carbon dioxide analyser. The zirconia fuel cell is split into a 
sample and reference chamber. The cell is semi permeable to oxygen molecules and 
their movement generates a voltage that is measured by the cell, thereby allowing 
measurement of O2 in the gas sample. Carbon dioxide absorbs infra-red light and the 
analyser is split into two chambers (reference and sample) through which beams of 
infra-red light are focused. The light absorption in the sample chamber is compared 
to that in the reference chamber, thus allowing quantification of CO2 content. 
The CPX gas analyser was calibrated prior to every test using both reference 
(21% O2 and balanced N2) and calibration (12% O2, 5% CO2 and balanced N2) gases 
(Medgraphics Corporation, St. Paul, Minnesota, USA). System response time or 
“phase delay” was checked and then ambient O2 and CO2 measurements were 
checked using the inbuilt on-line calibration system. 
The air-flow calibration was made via a pitot tube, attached at 90 degrees to a 
pneumotachometer (pre Vent, Medgraphics Corporation, St. Paul, Minnesota, USA) 
that measured the differential pressure of gas flow against 2 small tubes. The 
pressure was dependent on gas density and was therefore, sensitive to changes in gas 
composition. The pressure measurement was converted to air flow by first 
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establishing a zero-flow baseline, followed by 5 withdrawals and injections of air 
made at different speeds using a 3-litre syringe. This range of speeds simulated the 
varying respiratory rates observed throughout an exercise test. A correction factor, 
generated during the calibration, was applied to reduce the variability that exists 
between pneumotachometer readings. 
Breath by breath gas sampling 
A mouthpiece and saliva trap was connected to a T-shaped non-rebreathing valve 
and the mouthpiece positioned in the subject’s mouth so as to create a perfect seal. A 
nose-clip was used to ensure 100% mouth breathing. The subject’s air sample was 
passed through a drying cartridge before entering the gas module, to remove any 
moisture that may cause contamination of the infra-red window and hence, 
inaccurate gas quantification. Inspired and expired gas samples were analysed 
breath-by-breath for oxygen uptake (VO2), carbon dioxide production (VCO2), 
respiratory exchange ratio (RER), end tidal partial pressure of carbon dioxide 
(ETpCO2), minute ventilation (VE), tidal volume (Vt) and respiratory rate (RR) 
using the Medgraphics CPX/D system (Medgraphics Corporation, St Paul, 
Minnesota, USA). Gas analysis output was presented as the mean 5 of 7 breaths to 
remove the confounding effects of large variations in ventilation. 
Resting respiratory data 
Respiratory data were collected continuously for 10 minutes prior to any cardiac 
output measurements.  Data were further collected for at least 10 minutes between 
each measurement. These tests were performed in a standardized, quiet environment.  
If necessary, as indicated by high resting RER values or high VE values, the subjects 
were encouraged to slow the work of their breathing. If a subject requested a break 
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from the mouthpiece, a further 10 minutes of resting sampling was obtained prior to 
any measurements. 
 
Resting and exercise ECG 
Prior to the commencement of each test all subjects were fitted with a 12-lead 
electrocardiogram (ECG). A continuous 12 lead ECG was recorded throughout the 
exercise test to measure maximal heart rate (HRmax). Heart rate was determined 
directly from the R-R interval of the ECG. 
Blood pressure measurements at rest and during exercise 
Systolic and diastolic arterial blood pressure was measured at the left brachial artery 
via manual auscultation and sphygmomanometry. All measurements of blood 
pressure were taken in accordance with the British Hypertension Society 
guidelines.165 The appropriate size cuff (width: 40-50%, length: 80% circumference 
of arm) was chosen for each subject and applied to the bare, upper arm to provide a 
firm but comfortable fit. The stethoscope was placed over the artery, just above the 
antecubital fossa; the cuff was inflated beyond the estimated systolic pressure, and 
then deflated at a rate of 2 mmHg per second. Systolic pressure was identified at the 
first Korotkoff sound (a repetitive, clear tapping sound for >2 consecutive beats) and 
diastolic at the fifth Korotkoff sound, after which all sounds disappeared.166  Under 
resting conditions, blood pressure was taken in the seated position with the arm 
supported at heart level by the treadmill support bar and after at least 3 minutes rest 
to allow the subject’s blood pressure to stabilise. During upright exercise, the 
subject’s arm was supported, again at heart level, on the investigator’s shoulder. 
Carbon dioxide rebreathing techniques for measurement of cardiac output 
The study subjects performed exercise upright on a treadmill. To enhance 
standardisation of testing, the participants were encouraged to use the hand rail and 
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to walk rather than run for as long as comfortable.  They had a manual 
sphygmanometer cuff attached to their left arm for regular blood pressure 
measurement every 3 minutes. If a patient with CKD had an arterio-venous fistula on 
the left arm, the right arm was used instead. The subjects wore a 12 lead ECG which 
was monitored continually throughout rest, exercise and recovery.  They breathed 
through the mouthpiece, enabling determination of gas exchange and flow with each 
breath. The bag was a non-latex anaesthetic bag, used to contain the carbon dioxide 
mixture. A valve is opened for the carbon dioxide measurements at rest and at peak 
exercise, so that they rebreathed from the bag rather than from room air for short 
periods during the rebreathing test.  
Cardiac output measurement 
Cardiac output was calculated by applying the indirect Fick equation: 
 
Where 
Cardiac output (Qt) is pulmonary blood flow in litres/minute 
VCO2 is carbon dioxide production in litres/minute 
CvCO2 is the venous concentration of carbon dioxide   
CaCO2  is the arterial concentration of carbon dioxide 
CO2 production: During cardiopulmonary exercise testing, CO2 production was 
measured directly, along with O2 consumption. 
Arterial CO2 concentration: It was assumed that there was equilibrium between the 
gas in the alveolar space and the pulmonary vein capillary bed. Therefore, the arterial 
CO2 partial pressure can be extrapolated from the end-tidal pressure of CO2 
(ETpCO2) using the following equation167: 
 
Computerised dissociation tables then convert partial pressure to concentration.168 
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Venous CO2 concentration: Calculation of venous CO2 concentration involves re-
breathing gas containing pre-determined concentrations of CO2 until the gas in the 
bag and alveolar gas are in equilibrium (and therefore equal to venous blood). 
This method of measuring cardiac output can be performed completely non-
invasively with no risk as the only gas required is carbon dioxide.  Several studies 
have been performed in the past using the technique.154,169,170 Previous studies have 
confirmed the technique to be valid and reproducible,171,172 and accuracy may be 
preserved with the automated calibration systems used in this study. 
There are two methods for determining cardiac output; Collier 173 determined 
venous CO2 from a plateau achieved when inspired and expired CO2 partial pressures 
reach equilibrium after elevation of alveolar CO2, achieved by re-breathing CO2 from 
a bag at a higher concentration than the alveolar space. Defares 174 determined 
venous CO2 concentrations by initially re-breathing a low concentration of CO2. 
Here, equilibrium is not reached; venous CO2 is calculated from the exponential rise 
in ETpCO2 during re-breathing. Collier’s method is more accurate for resting 
measurements whilst Defares’ method is more accurate for peak exercise 
measurements. To improve the accuracy of the measurements, two measurements are 
taken for the resting CO and two measurements for the peak CO. 
The Collier method (equilibrium) 
The Collier method of rebreathing utilises a medical grade gas mixture comprising 
10% CO2, 35% O2 and balanced N2 to provide an initial partial pressure of CO2 
(pCO2) greater than the subject’s mixed venous CO2 tension (pvCO2). The high 
content of O2 (35%) is sufficient to maintain normal arterial saturation throughout 
the rebreathing procedure. The gas mixture, at a volume 1.5-2.0 times the subject’s 
resting tidal volume (VT), is re-breathed from a 5 litre anaesthetic bag via closed 
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circuit spirometry. The gases in the bag and alveoli mix, a fall in pCO2 occurs 
resulting in equilibrium between the lung-bag system and pvCO2 that is indicative of 
no further gas exchange.  The equilibrium (seen as a plateau on the CO2 graphical 
Breeze output) occurs between 8-12 seconds from the start of the re-breathing 
manoeuvre and must be maintained within 1mmHg for at least 2 respiratory cycles. 
At this point pCO2 is assumed to equal pvCO2. 
Continuous end-tidal CO2 (ETpCO2) readings taken for the preceding 30 
seconds before the start of the re-breathing manoeuvre provide a value for alveolar 
pCO2 (pACO2) from which arterial CO2 tension (paCO2) can be derived using tidal 
volume (VT) from the equation: paCO2 = 5.5 + 0.9 (ETpCO2) – 0.0021 (VT). For 
the calculation of cardiac output using the indirect Fick equation it is essential to 
convert the partial pressures of CO2 (paCO2 and pvCO2) into the content of CO2 
(CaCO2 and CvCO2). This then allows determination of the difference in veno-
arterial content (CvCO2-CaCO2) using the CO2 dissociation curve for whole blood.  
 
Fig 2.1: Equilibrium curve obtained at rest employing Collier’s method of cardiac 
output determination. 
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The Defares’ method (exponential)174 
A gas mixture comprising 4% CO2, 35% O2 and balanced N2 is utilised in this 
method for measurement of mixed venous CO2 tension (pvCO2). Once again, the 
high content of O2 is sufficient to maintain normal arterial saturation throughout the 
rebreathing procedure and the gas mixture, this time at a volume approximately 1.0-
1.5L greater than the subject’s maximal tidal volume, is re- breathed from a 5 litre 
anaesthetic bag via closed circuit spirometry. The 4% concentration of CO2 is lower 
than that of the subject’s pvCO2 and results in an exponential increase in ETpCO2. A 
complete equilibrium between the lung-bag system and pvCO2 is never attained, 
unlike that occurring during the Collier method, and pvCO2 is mathematically 
calculated from the asymptotic rise in ETpCO2. Calculation of pvCO2 via this 
method during non-steady state maximal exercise has proven to be more accurate 
when compared to the Collier method,175,176 and the lower CO2 concentration is 
better tolerated by the subject. 
Exercise testing protocol 
The exercise tests were performed in three stages. The first stage was to measure 
resting CO, HR, VO2 and BP.  It was performed seated, after a resting period of at 
least 30 minutes. This test was performed when no significant exercise had taken 
place in the previous 24 hours. The second stage was an incremental test to 
determine the peak oxygen consumption (VO2), heart rate (HR), blood pressure (BP) 
and anaerobic threshold (AT). This is performed by treadmill exercise according to 
the Bruce protocol.177 The third stage is used to measure peak cardiac output (CO). 
Familiarisation and standardisation 
Patients were made familiar with the exercise equipment and introduced to the staff 
at the start of the study. The purpose of the studies and the procedures were 
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explained in full before written consent was obtained. The second stage of 
incremental exercise was always performed prior to the third stage. 
This was therefore used as a familiarisation study.  Where there is 
discrepancy between the results of the second and third stages, the third stage results 
were used to reduce the effect of familiarisation with the equipment and testing 
protocol. From the two tests performed at each exercise session, the higher VO2 
value from either test was used. 
Exercise testing was conducted on the same Marquette 2000 treadmill 
(Marquette Electronics, Milwaukee, USA) throughout the studies, using standard 
Bruce protocols.177 The same supervisors conducted the tests throughout. All tests 
were performed three hours postprandial.  
Calibration 
The gas analysis system was calibrated before each test. The pneumotachograph, 
which is used to measure gas volumes, was calibrated manually with a 3-litre syringe 
(Cardiokinetics, Salford, UK) by five injections and withdrawals, representing 
fluctuations in respiration, after a no–flow baseline is established. The O2 and CO2 
analysers were also calibrated using bottled gases. The ambient room pressure was 
checked daily with a calibrated barometer. 
Stage one - Resting test 
Subjects rested for 10 minutes in the sitting position, to allow HR, BP and respiration 
stabilise. A mouthpiece was positioned in the subject’s mouth with a nose clip to 
ensure mouth breathing. Further resting time was allowed once the mouthpiece was 
in position, to allow for any changes in respiration due to anxiety.  To standardise 
each test, the measurements were taken when the minute ventilation (VE) was less 
than 10 L and the end-tidal CO2 greater than 30 mmHg. Continuous respiratory, HR 
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and ECG (3 lead) monitoring was performed. Resting CO was then measured using 
the CO2 re- breathing method of Collier as previously described. A 5 litre anaesthetic 
bag was connected to the pneumotachograph via a three-way tap. The bag was filled 
with 10% CO2 35% O2 and balanced nitrogen, to a volume of twice the subject’s 
resting tidal volume. 
At end expiration, the three-way tap was altered so the subject breathed from 
the gas in the closed anaesthetic bag. The concentration of CO2 in the bag exceeds 
the subject’s concentration of CO2 in their venous (pulmonary capillary) blood and 
the diffusion gradient between the venous blood and alveolar space are reversed. 
Equilibrium is achieved over four to five breaths. The computer is programmed to 
recognise equilibrium at the point where the difference between inspired and expired 
CO2 is less than 0.1% in two successive breaths. Calculation of the partial pressure of 
CO2 in the venous blood is automatically made and CO is calculated using the 
indirect Fick equation. At least three measurements of CO are made in order to 
calculate an average.  Each test is performed several minutes apart, to allow for the 
washout of CO2 from the circulation and to let the resting VE and ETpCO2 return to 
stable baseline. Resting BP is measured initially, and then following each CO 
measurement. HR is measured continuously, but is recorded at the start of each CO 
measurement. Resting CPO involves measuring both BP and CO in a seated position. 
Stage two – Incremental test 
A mouthpiece was positioned in the subject’s mouth with a nose clip to ensure mouth 
breathing. A minute of standing rest was given before starting the incremental test to 
allow the subjects to get used to the mouthpiece. VO2 (mls.min-1), VCO2 (mls.min-1), 
end tidal partial pressure of carbon dioxide (ETpCO2, mm Hg), tidal volume (VT, L), 
and respiratory rate (RR, min-1) were recorded breath-by- breath using the 
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Medgraphics CardiO2 analytic system (Medical Graphics Corporation, St Paul, 
Minnesota, USA). Respiratory exchange ratio (RER = VCO2/VO2), minute 
ventilation (VE = VT x RR, l.min-1), and VO2/kg (VO2/weight, mls.kg-1.min-1) were 
calculated from the above variables. 
Predicted peak VO2 was calculated by the Wasserman technique for males: 
weight x [50.72 – (0.372 x age)].178 Various ventilatory indices were calculated from 
the above data:  ratio of minute ventilation to O2 consumption at 1 litre of O2 
(VE/VO2 1l O2) and at peak exercise (peak VE/VO2), ratio of minute ventilation to 
CO2 production at peak exercise (peak VE/VCO2). The regression slopes relating 
minute ventilation to O2 consumption (VE/VO2 slope) and CO2 production 
(VE/VCO2 slope) were also calculated. The V-slope method179 was used to calculate 
the anaerobic threshold (AT). 
Subjects were verbally encouraged to exercise to exhaustion, and their 
limiting symptom (e.g. breathlessness or leg fatigue) was recorded. All patients 
performed symptom-limited exercise tests unless termination was indicated for 
safety reasons e.g. exercise induced hypotension or significant cardiac arrhythmia. 
Attainment of an age-predicted heart rate was not used as a criterion for stopping the 
test. The Borg score of perceived breathlessness and leg fatigue was checked every 3 
minutes as a safety check because the subjects are not able to talk, and to gauge 
perceived exertion.180 
A 12-lead electrocardiogram (ECG) was monitored throughout, and recorded 
at baseline, every 3 minutes and to record any abnormalities, e.g. ventricular ectopic 
beats. Blood pressure was measured manually using a sphygmomanometer (first 
Korotkoff sound used for systolic BP and fifth sound for diastolic BP) at baseline, 
two minutes into each stage, at peak exercise and during recovery. A maximal test 
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was considered if the respiratory exchange ratio (RER) is greater than 1 or if there is 
a plateau in VO2 despite further increases in workload. 
Maximal exercise testing 
In terms of true exercise physiology, the definitive ascertainment of VO2max requires 
a levelling off of peak VO2 despite increasing intensity of exercise.181,182  It is widely 
recognised that this is achievable only in elite athletes, and unattainable even in 
healthy normal subjects, especially those who are sedentary and unaccustomed to 
endurance exercises. To set this as a necessary condition of determining true 
maximal exercise would be unrealistic when studying sedentary subjects. The peak 
VO2 obtained during an incremental exercise test gives a reasonable approximation 
of VO2max for that exercise model. For the purposes of these investigations, we 
defined VO2max to be the highest VO2 attained at volitional maximal symptom-
limited exercise.  
Taylor182 comments that some normal subjects, as well as patients who may 
have become fatigued, discouraged or debilitated, may not be willing to push 
themselves to the point which produces the maximal oxygen uptake. This may be a 
limitation of the study. We elected to let the patients reach their self-determined 
volitional maximum.  Verbal encouragement was provided, but it was deemed 
unwise to excessively push any of the subjects. The necessary conditions required to 
determine whether peak exercise has been reached were (i) that the individual subject 
dependably stated that they had reached a volitional exercise limit, whatever the 
cause (e.g. dyspnoea, fatigue, exhaustion), and (ii) a peak RER of greater than 1.05. 
The other variables monitored would be subsequently used during analyses of data to 
determine comparability of exercise end-points in the contrasting cohorts, as an aid 
to correct interpretation of experimental data in order to consider the 
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pathophysiological mechanisms responsible. Stage two also serves as a 
familiarisation step for stage 3 when the non-invasive cardiac output measurement is 
carried out. 
Resting period between incremental and peak exercise tests 
A rest period of at least 30 minutes (usually more) was required between the two 
maximal exercise tests. To prevent hyperthermia, subjects were encouraged to drink 
water during the rest periods.  
Stage three - Peak exercise cardiac output 
The third stage was to measure peak cardiac output. Defares’ method was used to 
calculate CO at peak exercise, again using the indirect Fick equation. Subjects 
performed a constant maximum workload exercise test for at least five minutes, 
targeted for the same VCO2 as that obtained during the incremental test as it was 
found that this achieved a peak VO2 of at least that obtained at maximum level 
during the first stage. Subjects were encouraged verbally throughout and were told 
the VCO2 goal that they were trying to achieve, which could be seen on the screen. 
At peak exercise, the anaesthetic bag was filled with 4% CO2, 35% O2 and balanced 
nitrogen, to more than twice the patient’s tidal volume. The three-way tap was 
adjusted so the patient breathed from the bag for 10 seconds in order for the 
computer to construct a graph of end tidal points. The treadmill speed was briefly 
reduced to ensure subject comfort, obtain peak blood pressure and change the 
contents of the bag.  The participant then exercised back to his peak again and the 
measurement was repeated, in order to take an average. The computer applies a best-
fit exponential curve to the points according to the technique of Heigenhauser and 
Jones 183 rejecting the first point, and using 8 seconds of re- breathing to create an 
71 
 
 
exponential curve. End tidal points were manually adjusted to obtain the most 
accurate exponential curve. 
 
Calculations 
• Mean arterial pressure (MAP) has physiologic and clinical importance as it 
represents the tissue perfusion pressure. Mean arterial pressure is calculated 
using the Meaney formula.184    
 
SBP and DBP are systolic and diastolic blood pressures measured in mmHg. 
 
• Cardiac power output (expressed in watts) is calculated from the equation 
described by Cooke et al 161  
 
k is the conversion factor into watts, k = 2.22 x 10-3. 
• Cardiac functional reserve was calculated as the difference between peak and 
resting cardiac power output  
∆CPO = CPOmax - CPOrest.  
• Stroke work (SW) was calculated as the product of stroke volume and mean 
arterial pressure. 
• Systemic vascular resistance (SVR) was also calculated. 
 
The conversion factor 80 is used to convert Woods unit (mmHg.min.l-1) into 
dyn.sec.cm-5. 
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2.5.2 Investigation 2: Echocardiogram 
A subgroup of patients (n=54) who underwent CPX testing took part in the 
echocardiography studies. Echocardiography was performed by a qualified senior 
echocardiographer. The subjects were scanned within 8 weeks after CPX testing. On 
the day of the test, a 3-lead ECG was attached to the subject and then they were 
rested in the left lateral position for 10 minutes in a quiet, warm room. All studies 
were performed using a GE Vingmed VIVID 7 (Horten – Norway) and images were 
post-processed on a dedicated Echopac PC.  
A 2-dimensional study was performed in the standard parasternal long axis 
and short axis planes followed by an apical 4-chamber, apical 5-chamber and apical 
2-chamber planes to evaluate cardiac structure and left ventricular contractility. In 
the parasternal long axis M-mode studies were performed in the left ventricle, at the 
end of the mitral tips. A frozen M-mode image was used to measure ventricular wall 
thickness and chamber size, in end diastole (EDD) at the peak of the R wave on the 
ECG and end systole (ESD) at the point of closest approximation of the posterior 
wall and the interventricular septum. Left atrial size was measured at the widest point 
during atrial diastole. Left ventricular ejection fraction (LVEF) was calculated by 
Simpson’s biplane method185 and left ventricular mass index (LVMI) was calculated 
by Devereaux method.186 
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2.5.3 Investigation 3: Biomarkers  
Sample collection: Blood samples were obtained from study subjects prior to 
exercise testing. The sample was immediately centrifuged and the serum is stored as 
0.5 ml aliquots in -80°C freezer. 
Uraemic retention solutes: Indoxylsulphate, p-cresylsulphate, p-cresylglucuronide, 
indole acetic acid, hippuric acid, uric acid, β2M, 3-carboxy-4-methyl-5-propyl-2-
furanpropionic acid (CMPF), asymmetric and symmetric dimethylarginine (ADMA 
and SDMA) were assayed in Ghent University Hospital, Ghent, Belgium.90,187 
Quantification of the suggested uraemic retention solutes  
 HPLC Analysis: Assays are performed on samples collected at the time 
of CPX. For determination of the total fraction, serum samples are deproteinized by 
heat (95°C, 30 min). After cooling (10 min on ice), samples are filtered through a 
Centrifree-filter (Millipore, Billerica, MA). The ultrafiltrate is injected onto the 
column. To determine the free fraction, untreated serum samples are filtered through 
Centrifree prior to heating. Indoxylsulphate, indole-3-acetic acid, p-cresylsulphate 
and p-cresylglucuronide are determined by fluorescence analysis, while hippuric 
acid, CMPF and uric acid are analysed by UV detection [Waters Alliance 2695 
device (Waters, Zellik, Belgium) connected to a Waters fluorescence and a UV 
detector]. 
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2.5.4 In vitro analysis 
The study was conducted in the faculty of biological sciences at the University of 
Leeds, Leeds, UK. 
Cardiomyocyte isolation 
Single ventricular cardiac myocytes were isolated from male Wistar rats 
(approx.250g). Hearts were removed following sacrifice by Directive 2010/63/EU 
approved methods. Hearts were quickly removed and placed in a solution (modified 
Tyrode’s solution) containing (in mmol/l): 130 NaCl, 5.4 KCl, 0.4 NaH2 PO4, 1.4 
MgCl2·6H2O, 5 HEPES, 10 glucose, 10 taurine, 20 creatine and 0.7 CaCl2 (pH 
adjusted to 7.3 with NaOH). Excess tissue was trimmed and the heart was cannulated 
on a Langendorff apparatus via the aorta (Fig 2.2); through which solution was 
already flowing at a constant rate of 8 ml/min to prevent air bubble formation in the 
coronary circulation. The heart was held in place with an artery clip then surgical 
suture thread was tightened around the aorta and glass cannula, ensuring sufficient 
perfusion pressure. All solutions were held in reservoirs where they were continually 
gassed with 100% O2 and the temperature maintained at 37°C. 
The heart was perfused until the superficial vessels had cleared of blood. 
A second Tyrode solution lacking Ca2+ and containing Ca2+ chelating agent EGTA 
(0.5mM) was then perfused for 4 min to stop contractions. This is thought to protect 
cells during the isolation procedure by inducing closure of gap junctions and 
weakening intercellular connections. A third Tyrode solution containing 0.05 mM 
Ca2+, 1 mg/ml collagenase (Type II, Worthington Biochemical, USA) and 0.1 mg/ml 
protease (Type XIV, Sigma, UK) was perfused for 7 minutes; this digests the 
extracellular matrix and allows cardiomyocytes to separate. Enzyme solution could 
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be recirculated should the heart require more time to digest, otherwise it was 
collected and used in subsequent steps of the isolation procedure. 
 The heart was cut down from the cannula and the LV and RV were 
carefully dissected from the septum and coarsely minced in separate conical flasks in 
enzyme solution. The ventricle tissue was shaken in enzyme solution in a 37°C water 
bath to loosen cell attachments.  Every 4 minutes the tissue was strained through 
nylon mesh and the remaining tissue was returned to the flask and the procedure 
repeated to give 4 or 5 separate fractions of cells. The collected enzyme solution was 
centrifuged at 50 x g for 40 s forming pellet of cells. Centrifuging at this speed helps 
separate dead cells, which stay in solution, from live cells which form a pellet. The 
supernatant was discarded and the pellet resuspended in 1 mM Ca2+ Tyrode and 
stored in a centrifuge tube at room temperature and used within 10 h. If the heart did 
not perfuse properly and became hypoxic or did not digest, the cells were not used 
for the study. 
 
 
 
Figure 2.2: An example of the cardiomyocyte isolation set up where the heart is 
cannulated on a Langendorff apparatus 
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Light microscope set up 
A drop of cells was placed in a superfusion chamber on the stage of an inverted 
microscope (Eclipse TE300, Nikon, Japan) fitted with a 40X objective. Cells were 
viewed through the eyepiece and a video image of the cells was acquired using a 
video camera (Myocam-S, Ionoptix, USA) mounted to the side of the microscope 
and displayed on a computer monitor facilitating simultaneous edge detection, 
sarcomere analysis and fluorescence experiments using IonWizard software 
(IonOptix, USA) (Fig 2.3). The cell bath was perfused with solutions in reservoirs 
suspended above the microscope which could be warmed by a heater prior to 
entering the cell bath. 
 
 
Figure 2.3: An example of the light microscope set up to measure cardiomyocyte 
contractility. The reservoirs containing experimental solutions are not shown in this 
picture. 
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Cell morphology and resting sarcomere length 
Cells were considered viable for experimentation if they appeared rod shaped with 
clear striations and were quiescent in the absence of stimulation. Average sarcomere 
length (SL) was measured by fast Fourier transform of an area of the cell, giving the 
dominant frequency of oscillations in contrast between light and dark bands which 
was automatically converted to length in microns in IonWizard.  
 
 
 
Figure 2.4: Example of viable a cell used for experimentation. 
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Experimental Solutions 
The experimental (Tyrode) solution contained (in mmol/l): 137 NaCl, 5.4 KCl, 0.33 
NaH2 PO4, 0.5 MgCl2 ·6H2O, 5 HEPES, 5.6 glucose, and 1.8 CaCl2 (pH adjusted to 
7.4 with NaOH). Indoxyl sulphate (IS) (Sigma-Aldrich, Bornem, Belgium) was 
dissolved in saline to prepare the (300x) stock solution. The effect of indoxylsulphate 
(IXS) was assessed by switching the superfusion solution to Tyrode solution 
containing IXS at a final concentration of 4.49 mg/l, the maximum reported free 
concentration in uraemia. 188-190 IXS stock solution was tested for lipopolysaccharide 
contamination by a kinetic chromogenic Limulus amoebyte lysate test (Lonza, 
Vervier, Belgium). 
Measuring sarcomere shortening 
The cells were field stimulated via platinum bath electrodes using a 5-ms pulse at a 
stimulation frequency 1 Hz.  Diastolic SL, systolic SL, fractional shortening (defined 
as a percentage change from diastolic SL) and the time constant of an exponential fit 
to the time course of the relaxation (Tau) were measured by averaging 10 – 15 
twitches in each cell (Fig 2.5). The cells were initially superfused with the Tyrode’s 
solution then switched to the solution containing IXS for at least five minutes 
exposure, then switched back to Tyrode’s solution to assess the wash off effect.  
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Figure 2.5: A representative trace of sarcomere length change during stimulation at 1 Hz. 
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Inhibition of Protein Kinase A 
To inhibit the action of Protein Kinase A (PKA), cells were incubated in storage 
solution with 100 µmol/l Rp8-Br-cAMPS (Rp8, Santa Cruz Biotech, USA), for at 
least 30 minutes.  
Measurement of calcium transients 
Intracellular calcium ([Ca2+]i) was simultaneously monitored with SL using the 
fluorescent Ca2+ probe, Fura-2 AM (Molecular probes, USA). Isolated cells were 
loaded with Fura-2 AM (3.1 µmol/l for 10 min) at 20–23°C, re-suspended in Tyrode 
solution, and left for at least 30 min to allow de-esterification of the dye. Myocytes 
were placed in the experimental chamber and were alternately illuminated with 
excitation light at wavelengths 340 and 380 nm using a monochromator 
spectrophotometer system (Optoscope, Cairn Research, UK). Emitted light at 510 
nm was collected by a photo- multiplier, and the ratio of emitted light in response to 
340- and 380-nm illumination (340-to-380-nm ratio) used as an index of [Ca2+]i. The 
calcium transient amplitude was the difference between the diastolic and peak 
systolic 340-to-380-nm ratio. Myocytes were stimulated in Tyrode solution (Con) for 
2 min before exposure to Tyrode plus IXS for 5 min then returned to control for 2 
min. 
Fluorescence spectrophotometry 
To test for the possibility that IXS had a direct action upon the fluorescent indicator, 
Fura-2, the effect of IXS on the excitation spectra of Fura-2 was tested using the 
Optoscope. Fluorescence of Fura-2 free acid  at 510nm, was measured in solutions 
containing (in mmol/l) 132 KCl, 1 MgCl2, 1 EGTA and 10 HEPES together with 1 
mmol/l EGTA and CaCl2 at appropriate ratios to give the desired pCa.191 The 
wavelength of the excitation light was increased from 300 to 400 nm in 5nm steps. 
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IXS in 140mmol/l NaCl was added to the experimental solution to give a final IXS 
concentration of 4.49mg/l and compared with that of the experimental solution with 
an equivalent volume of 140mmol/l NaCl. 
2.6 Statistical analysis 
Clinical study: CPOmax was the primary outcome measure. The CKD 5 patients were 
slightly older compared to the controls. In order to correct for the age difference, 
CPOmax is also presented as a percentage of predicted values for the age in addition 
to the absolute values. The percentage predicted values for the age was obtained 
from the historical control cohort of 101 sedentary healthy male volunteers. 
Comparison of CPOmax of the controls and the study groups was performed using 
Independent sample t-test. The variations in CPOmax and other study parameters 
across the study groups were analysed with analysis of variance ANOVA. The 
association between CPOmax and various haemodynamic and biochemical variables 
were assessed by Pearson’s correlation. As the exposure variables suffered strong co-
linearity, their independent association with CPOmax was assessed using partial least 
squares multiple regression analysis.192,193 Results are presented as mean±SD 
(standard deviation). P<0.05 is considered statistically significant. SPSS 17.0 (IBM, 
USA) statistics software was used in the analysis. 
Sample size: Based on the results of the pilot study of first 11 patients,194 to 
demonstrate 10% difference in CPOmax between study groups and healthy controls 
(with 90% power) a minimum of 11 patients per group was required. 
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In vitro studies: Data are expressed as means ± SEM (standard error mean). 
Statistical significance was tested using repeated measures ANOVA and independent 
sample t-tests where appropriate using SPSS statistics software version 17 (IBM, 
USA). Statistically significant difference was assumed when P < 0.05. Myocyte 
numbers for each experiment are given in the relevant figures/tables. 
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CHAPTER 3 
 
Study 1 
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3.1 Introduction 
This has been described in the full introduction chapter, but a brief description is 
given here. Heart failure (HF) is highly prevalent in chronic kidney disease (CKD) 
and confers a serious adverse prognosis.195-197 Therefore, identification of early 
cardiac dysfunction and an understanding of the pathophysiology of such 
dysfunction are vital in preventing the emergence and progression of heart failure in 
CKD.  
However, whether HF is a complication of the common co-morbidities of 
CKD such as ischaemic heart disease (IHD) and diabetes mellitus (DM), or whether 
CKD per se can cause cardiac impairment remains to be answered. Furthermore, it is 
not known whether asymptomatic cardiac dysfunction, the precursor of heart 
failure,198 is present in CKD. 
As described in the introduction, cardiac structural and ultrastructural 
changes in CKD have extensively been studied using techniques such as 
echocardiogram,7 cardiac magnetic resonance imaging132 and cardiac biopsy123 
offering valuable insights into uraemic cardiomyopathy by exposing abnormalities 
such as left ventricular hypertrophy (LVH), cardiac fibrosis and myocyte-capillary 
mismatch. However, attempts to detect cardiac dysfunction in asymptomatic CKD 
patients before they develop overt symptoms of heart failure have so far been 
unsuccessful. In a recent large echocardiographic study,199 no relationship between 
resting measures of systolic and diastolic cardiac dysfunction and renal dysfunction 
in asymptomatic CKD patients was found. Alternatively, functional measures of 
peak performance of the heart have the potential to reveal subclinical cardiac 
dysfunction.  
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In Study 1 of this thesis, I tested the hypothesis that asymptomatic CKD 
patients have impaired peak cardiac power output and hence reduced cardiac 
functional reserve. Moreover, I tested CKD patients without primary cardiac disease 
or DM to study the effect of CKD-specific factors in isolation. 
3.2 Methodology 
Full methodology is discussed in Chapter 2. A concise methodology relevant to 
Study 1 is presented here. 
 
Study subjects 
Asymptomatic male patients (n=70) aged over 18 years, mean 48.4±12.6 years, with 
CKD stable for 3 months (stages 2 to 5) were recruited from the renal outpatient 
clinic in Leeds for cardiopulmonary exercise testing (CPX). A detailed clinical 
history was obtained and clinical examination performed. Exclusion criteria were as 
listed in the methods chapter (Chapter 2, page 55). Venous blood samples were taken 
at the time of recruitment to assay serum creatinine, urea, haemoglobin, serum 
calcium, inorganic phosphate and parathyroid hormone. Urine samples were assayed 
for urine protein-creatinine ratio. Estimated glomerular filtration rate (eGFR) was 
calculated using the 4-variable modification of diet in renal disease MDRD 
formula.11  
Cardiopulmonary exercise tests (CPX) 
Peak cardiac power output (CPOmax) was determined noninvasively during maximal 
cardiopulmonary exercise (CPX) testing. Full methodological details have been 
described in the previous chapter.161 In summary, the subjects had baseline 
measurements for O2 consumption, CO2 production and resting cardiac output. 
Resting cardiac power output was calculated.173,200 Subjects were then exercised on a 
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treadmill according to a standard Bruce protocol, until the subjects reached volitional 
exhaustion. Throughout the treadmill test, O2 consumption, CO2 production, end-
tidal partial pressure of CO2, tidal ventilation, and respiratory rate were measured 
using breath-to-breath analysis. Ventilatory (‘anaerobic’) threshold was measured by 
V-slope method.179 After resting at least 40 min, a second treadmill test was 
performed to obtain maximum workload. The speed and incline of the treadmill were 
increased or decreased to allow each subject to sustain exercise for at least 5 min. 
During this exercise, the subjects needed to sustain a rate of O2 consumption of at 
least 95% of that achieved in the initial treadmill exercise. Two or three cardiac 
output measurements were made using the Defares CO2 rebreathing method.174 The 
mean arterial blood pressure (MAP, mmHg) was calculated as 
MAP=DBP+0.412(SBP–DBP), where DBP is diastolic blood pressure and SBP is 
systolic blood pressure.184 Cardiac power output (CPO), expressed in watt (W), was 
calculated 149  
3.2.1 Statistical analysis 
CPOmax was the primary outcome measure. In order to correct for the age difference, 
CPOmax is also presented as a percentage of predicted value for age based on 
previous studies on healthy volunteers in the unit.161 Comparison of CPOmax among 
the study groups was performed using independent sample t-tests. Variations in 
CPOmax and other study parameters across the study groups were analyzed by 
ANOVA. The association between CPOmax and biochemical variables was assessed 
by Pearson’s correlation. The haemodynamic determinants of cardiac reserve were 
evaluated using step-wise multiple regression analysis. Results are presented as 
mean±SD. P<0.05 was considered statistically significant.  
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3.3 Results 
3.3.1 Subject characteristics 
Anthropometric and biochemical characteristics of the study subjects are listed in 
Table 3.1. There were 70 male CKD patients with a mean age of 48.4±12.6 years 
covering the spectrum of CKD from stages 2 to 5 (CKD 2-5, pre-dialysis). The mean 
eGFR was 33.9±23.5 ml/min (CKD 5: 12.3±2.3 ml/min, CKD 4: 22.2±3.9, CKD 3: 
43.2±7.9, CKD 2: 73.5±7.9 ml/min). The etiologies of CKD were as follows 
(number of patients in brackets): IgA nephropathy (19), polycystic kidney disease 
(15), reflux nephropathy & chronic pyelonephritis (15), membranoproliferative 
glomerulonephritis (3), Alport’s nephropathy (2), interstitial nephritis (1), 
hypertensive nephropathy (1), focal segmental glomerulosclerosis (3), minimal 
change disease (1) and uncertain etiology (10). None of the patients had a history of 
primary cardiac disease (ischaemic, arrhythmic or valvular) or diabetes mellitus. 
Patients had no cardiac symptoms and thus all were in New York Heart Association 
(NYHA) class I. No patient had electrocardiographic evidence or symptoms of 
angina pectoris, myocardial ischaemia or arrhythmia during exercise testing. None 
had uncontrolled hypertension (mean resting SBP was 113.9±12.5 and DBP was 
72.3±8.1 mmHg). Of the 70 patients, 61.4% were receiving angiotensin converting 
enzyme inhibitors (ACE-I), 34.8% angiotensin receptor antagonists and 20.0% β-
adrenoceptor antagonists. The average numbers of anti-hypertensive agents taken per 
patient in CKD 2-3a, CKD 3b-4 and CKD 5 were 1.2, 1.6 and 1.7 respectively. For 
comparison, Table 3.1 also shows data from age- and sex-matched contemporaneous 
patients with confirmed heart failure (HF) in functional NYHA classes II & III 
recruited from cardiology outpatient clinics (n=25), who served as positive controls.  
  
88 
 
 
Table 3.1: Body composition and biochemical characteristics of study subjects 
 Control 
(n=101) 
CKD 2-3a 
(n=21) 
CKD 3b-4 
(n=27) 
CKD 5 
(n=22) 
P HF 
(n=25) 
Age  
(years) 
43.2±18.
1 
42.5±11.0 49.4±11.5 52.9±13.6 <0.05 49.4±14.6 
BMI 
(kg/m2) 
26.0±3.1 27.5±3.8 27.6±4.0 28.4±3.9 NS 25.1±3.2 
BSA (m2) 1.9±0.1 2.07±0.15 1.99±0.18 2.03±0.17 NS 1.93±0.18 
  
eGFR 
(ml/min) 
-- 65.8±13.1 26.5±7.8 12.3±2.3 <0.05 69.3±16.9 
Creatinine 
(µmol/l) 
-- 114.9±18.6 254.9±67.9 504.5±174.
5 
<0.05 110.4±22.
8 
Urea 
(mmol/l) 
-- 8.3±2.4 17.9±5.0 25.9±7.1 <0.05 7.9±2.0 
Haemoglob
in (g/dl) 
-- 15.0±1.2 13.2±1.5 11.9±1.2 <0.05 14.4±1.13 
Calcium 
(mmol/l) 
-- 2.34±0.08 2.34±0.11 2.29±0.17 NS -- 
Phosphate 
(mmol/l) 
-- 1.08±0.18 1.22±0.15 1.53±0.55 <0.05 -- 
Bicarbonat
e (mmol/l) 
-- 27.24±3.02 23.74±3.15 21.32±2.97 <0.05 -- 
PTH 
(pmol/l) 
-- 12.28±24.1
7 
20.81±15.23 43.18±30.3
9 
<0.05 -- 
Urine PCR 
(mg/mmol) 
-- 25.99±28.9 96.44±112.5
2 
130.94±14
0.94 
<0.05 -- 
 BMI: body mass index, BSA: body surface area, CKD: chronic kidney disease, HF: heart failure, 
PTH: parathyroid hormone, PCR: protein creatinine ratio. P value is for ANOVA across control and 
CKD groups.  
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3.3.2 Cardiopulmonary exercise test parameters 
All CKD patients successfully performed cardiopulmonary exercise test (CPX) to 
volitional exhaustion with a mean duration of 10.5±2.9 min (Bruce protocol 
equivalent), mean peak respiratory exchange ratio (RER) of 1.16±0.09, a peak end 
tidal pCO2 (ETpCO2) of 37.2±5.9 mmHg, and maximal aerobic capacity (VO2max) 
was 2.51±0.53 l/min (equivalent to 91.1±17.0% of average controls). The HF 
patients exercised for 5.5±2.8 min (Bruce protocol equivalent, P<10-6 vs CKD) with 
a mean RER of 1.1±0.2, ETpCO2 of 29.9±8.7 mmHg, and VO2max was 1.54±0.38 
l/min (equivalent to 57.5±15.2% of average age-matched controls, P<10-6 vs CKD). 
3.3.2.1 Resting haemodynamics 
There were no differences between the resting haemodynamic parameters such as 
heart rate, blood pressure and stroke volume across different stages of CKD (Table 
3.2 & Fig 3.1), whereas the resting cardiac output and resting cardiac power output 
showed a reducing trend with increasing severity of CKD. In contrast, the resting 
systemic vascular resistance (SVR) showed an increasing trend with increasing 
severity of CKD with a resting SVR in CKD 5 comparable to that of heart failure. 
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Table 3.2: Resting cardiopulmonary exercise parameters of study subjects  
Variables Control 
(n=101) 
CKD 2-3a 
(n=21) 
CKD 3b-4  
(n=27) 
CKD 5  
(n=22) 
HF 
 (n=25) 
HRrest 
beats/min 
65.7±10.6 76.7±14.3* 76.7±14.2* 76.0±11.8* 78.5±16.4* 
SBPrest 
(mmHg) 
123.3±11.7 110.5±11.2 114.4±13.1 116.5±12.6 100.8±19.4* 
DBPrest 
(mmHg) 
76.3±9.1 71.9±8.1 73.3±6.8 71.6±9.5 66.8±11.6* 
MAPrest 
(mmHg) 
95.6±9.4 87.8±7.8* 90.3±8.3* 90.1±9.4* 80.8±14.1* 
COrest (l/min) 4.9±1.2 5.3±1.3 4.6±0.7 4.4±0.9 4.05±1.17* 
SVrest 
(ml/min) 
75.5±20.6 71.1±14.3 63.5±13.7* 60.8±13.1* 56.3±21.1* 
SVRrest 
(dyn.sec.cm-5) 
1685.0± 
511.9 
1406.4± 
347.8* 
1634.2± 
346.1 
1739.5± 
450.5 
1694.3± 
435.3 
CPOrest (W) 1.03±0.22 1.05±0.29 0.92±0.15* 0.87±0.21* 0.72±0.26* 
 
HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial 
pressure, CO: cardiac output, SV; stroke volume, SVR: systemic vascular resistance, VO2max: peak 
oxygen consumption, CPOmax: peak cardiac power output. *P<0.05 vs Control on independent sample 
t-test. 
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Figure 3.1: Resting cardiopulmonary exercise parameters of the study groups.  
HR: heart rate, MAP: mean arterial pressure, CO: cardiac output, SV; stroke volume, 
SVR: systemic vascular resistance, CPOmax: peak cardiac power output, CKD: 
chronic kidney disease, HF: heart failure. *P <0.05 vs Control on independent 
sample t-test.  
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3.3.2.2 Peak haemodynamics 
A summary of all peak haemodynamic parameters are presented in Table 3.3. 
Table 3.3 Peak cardiopulmonary exercise parameters of study subjects 
Variables Control 
(n=101) 
CKD 2-3a 
(n=21) 
CKD 3b-4  
(n=27) 
CKD 5  
(n=22) 
HF 
 (n=25) 
RER 1.21±0.1 1.15±0.09 1.15±0.11 1.16±0.06 1.09±0.29* 
Peak HR 
(min-1) 
172.9±17.4 171.3±19.7 158.7±17.9* 148.7±24.9* 128.9±40.1* 
Peak SBP 
(mmHg) 
198.2±17.7 163.3±12.8* 159.6±17.9* 151.6±16.5* 115.7±33.8* 
Peak MAP 
(mmHg) 
119.5±11.6 114.3±8.5* 111.8±10.6* 104.7±10.5* 87.8±22.1* 
Peak CO 
(l/min) 
20.3±3.9 21.50±2.31 19.44±2.07* 18.26±2.60* 12.52±2.37* 
Peak SV 
(ml/min) 
117.7±18.2 132.4±17.9* 128.6±19.9* 129.2±24.5* 105.1±37.0* 
Peak SVR 
(dyn.sec.cm-5) 
492.2±118.8 430.6±60.1 464.1±77.1 465.9±67.6 593.2±237.6* 
VO2max (l/min) 2.98±0.9 2.91±0.46 2.48±0.43* 2.17±0.43* 1.54±0.38* 
% VO2max 100.0±17.9 98.1±16.7 91.3±16.9* 84.0±15.2* 57.5±15.2* 
CPOmax (W) 5.35±0.9 5.02±0.78 4.59±0.53* 4.02±0.73* 2.34±0.63* 
% CPOmax 100.0±15.5 95.1±13.0 88.2±10.1* 78.5±13.9* 44.8±11.3* 
Cardiac 
reserve ∆CPO 
(W) 
4.34±0.89 3.98±0.82 3.66±0.5* 3.15±0.68 1.62±0.6* 
 
HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial 
pressure, CO: cardiac output, SV; stroke volume, RER: respiratory exchange ratio, SVR: systemic 
vascular resistance, VO2max: peak oxygen consumption, CPOmax: peak cardiac power output. *P<0.05 
vs Control on independent sample t-test. 
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Peak cardiac power output (CPOmax) is impaired in CKD 
CKD patients showed graded decline in CPOmax with increasing severity of CKD 
(Table 3.3 & Fig 3.2). The CPOmax of the study groups were 5.35±0.9 W in control, 
5.02±0.78 W in CKD 2-3a, 4.59±0.53 W in CKD 3b-4 and 4.02±0.73 W in CKD 5 
and 2.34±0.63 W in HF. The variation in CPOmax across CKD groups was 
statistically significant (ANOVA P<0.05). Between groups, CPOmax in CKD 5 was 
significantly impaired compared to both CKD 3b-4 (P=0.003) and CKD 2-3a  
(P<10-4) but not as impaired as HF (P<10-4). CPOmax in CKD 3b-4 was significantly 
impaired compared to CKD 2-3a (p=0.026). In addition, the results are presented as 
percentages of the CPOmax values predicted for age. The results were CKD 2-3a 
95.1±13.0%, CKD 3b-4 88.2±10.1%, CKD 5 78.5±13.9% and in HF 44.8±11.3% 
(Figure 3.3). The cardiac functional reserve (∆CPO) also showed graded reduction 
across the study groups (Table 3.3 & Figure 3.4). 
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Figure 3.2: Graded reduction in absolute CPOmax across the study groups. 
CKD: chronic kidney disease, HF: heart failure. **P<10-3, *** P<10-6 vs Control on 
independent sample t-test. 
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Figure 3.3: Graded reduction in percentage CPOmax (age-corrected) across the study 
groups. CKD: chronic kidney disease, HF: heart failure. **P<10-3, *** P<10-6 vs 
Control on independent sample t-test. 
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Figure 3.4: Cardiac reserve (∆CPO) of study groups. CKD: chronic kidney disease, 
HF: heart failure, CPO cardiac power output. **P<10-3 for cardiac reserve vs 
Control, ***P>10-6 for cardiac reserve vs Control.
97 
 
 
 
Peak cardiac output and peak mean arterial pressure are impaired in different stages 
of CKD 
Figure 3.5 shows the differences in peak cardiac output (CO) and peak mean arterial 
pressure (MAP), the flow and pressure generating capacities of the heart 
respectively, across the study groups. Peak CO and peak MAP were significantly 
lower in CKD 5 compared to CKD 2-3a and CKD 3b-4 (P<0.05). However, the 
values were not as impaired as in HF (P<0.05).  
Peak heart rate and heart rate reserve are impaired in CKD 
The peak heart rate was significantly impaired in CKD 5 compared to CKD 2-3a and 
CKD 3b-4 (both P<0.05) but not as impaired as in HF (P<0.05) (Table 3.3). The 
heart rate reserve (HRR), measured as the difference between peak and resting heart 
rate across the study groups were CKD 2-3a 94.6±12.9, CKD 3b-4 82.1±15.4, CKD 
5 72.7±18.4 and HF 55.8±24.1 beats/min. The HRR in CKD 5 was significantly 
lower compared to other CKD groups (P<0.05). In addition, the age adjusted HRR is 
significantly lower in CKD 5 compared to other CKD groups (P<0.05) but not as 
impaired as in HF (P<0.05) (Figure 3.6).  
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Figure 3.5: Peak cardiac output (Pk CO) and peak mean arterial pressure (Pk MAP) 
across the study groups. CKD: chronic kidney disease, HF: heart failure. 
*P<0.05 vs Control on independent sample t-test 
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Figure 3.6: Age adjusted heart rate reserve in percentage across the study groups. 
CKD: chronic kidney disease, HF: heart failure. *P<0.05 vs Control on independent 
sample t-test. 
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Increase in stroke volume partially offsets reduced chronotropic reserve in CKD 
The components of peak cardiac output, the peak stroke volume and the peak heart 
rate are shown in Figure 3.7. The peak stroke volume (SV) in CKD stages were 
higher compared to control. The effect of impaired chronotropic reserve on cardiac 
output was partially offset by this increase in stroke volume.   
There is no difference in peak systemic vascular resistance across CKD groups 
Although the resting systemic vascular resistance (SVR) showed an increasing trend 
with increasing severity of CKD (Table 3.2), the peak SVR was comparable between 
CKD groups. The peak SVR of heart failure patients remained higher than all stages 
of CKD and control (all P<0.05) (Table 3.3).  
 
 
101 
 
 
 
Figure 3.7: Peak stroke volume (Pk SV) and peak heart rate (Pk HR) across the 
study groups. CKD: chronic kidney disease, HF: heart failure. *P<0.05 vs Control on 
independent sample t-test.
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3.3.2.3 Determinants of cardiac reserve in CKD 
The independent predictors of cardiac reserve (∆CPO) in CKD were identified on a 
stepwise multiple regression analysis. The increment in the pressure generating 
capacity of the heart (∆MAP, the difference between peak and resting MAP) was the 
strongest independent predictor (β=0.51, P<10-4) followed by the increment in the 
flow generating capacity (∆SV, the difference between peak and resting stroke 
volume) (β=0.49, P<10-4) and the chronotropic reserve (∆HR) (β=0.42, P<10-4). The 
other independent predictors were eGFR (β=0.23, P=0.003) and BMI (β=0.15, 
P=0.03). No independent association was demonstrated with haemoglobin (Hb) or 
systemic vasodilatory capacity (∆SVR).  
3.3.2.4 Association between CPOmax and CKD related biochemical parameters 
CPOmax had significant positive correlation with eGFR, haemoglobin and serum 
bicarbonate, and significant negative correlation with urea, parathyroid hormone and 
inorganic phosphate. No correlation existed with serum calcium and urine protein 
creatinine ratio (Figure 3.8). Independent association of individual biochemical 
variables with CPOmax could not be assessed because of strong co-linearity among 
the biochemical parameters. 
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Figure 3.8: Association between CPOmax and CKD-related biochemical parameters 
on Pearson’s correlation. PTH: parathyroid hormone. 
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3.3.2.5 Relationship between maximal aerobic capacity, peak cardiac output 
and peripheral O2 extraction 
Simultaneous measurements of CPOmax and VO2max in patients with CKD allowed 
evaluation of the determinants of these parameters in CKD. Furthermore, 
simultaneous measurements of VO2 and cardiac output at rest and peak exercise 
enabled calculation of arterio-venous difference in O2 concentration [C(a-v)O2] at 
rest and peak exercise for the first time in CKD patients using Fick’s equation VO2 = 
CO x C(a-v)O2. The differential role of central (cardiac output) and peripheral [C(a-
v)O2] determinants of maximal aerobic capacity is shown in Figure 3.9. Whereas in 
HF the reduction in VO2max was mediated primarily through reduction in cardiac 
output, in CKD impaired C(a-v)O2 played a significant role. Indeed, on a step-wise 
multiple regression analysis ∆C(a-v)O2 was the strongest predictor of the VO2 
reserve (VO2max – VO2rest) with a β value of 0.53 (P<10-6). The other independent 
predictors of VO2 reserve were (β and P values in brackets) ∆SV (β=0.32, P=10-3), 
∆HR (β=0.28, P=0.002), Hb (β=0.31, P=10-3), age (β=-0.28, P=10-3) and BMI 
(β=0.2, P=0.003). C(a-v)O2 showed strong correlation with VO2max (r=0.783, P<10-6) 
and haemoglobin level (r=0.41, P<0.001) in CKD. 
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Figure 3.9: Differential changes in peak cardiac output (Pk CO) and peak peripheral 
O2 extraction C(a-v)O2 across the study groups. Aerobic capacity in CKD is reduced 
as a result of reduction in both cardiac output and C(a-v)O2 unlike in heart failure 
where reduction in cardiac output is the predominant factor.  CKD: chronic kidney 
disease, HF: heart failure. *P<0.05 vs Control on independent sample t-test. 
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Effect of beta blockers on central haemodynamics in CKD patients 
Linear regression was performed, controlling for eGFR, to compare haemodynamic 
parameters between CKD patients who were on beta blockers and those who were 
not. Results showed that there were no significant differences in peak CPO, peak CO 
and peak MBP. The mean peak CPO was lower in the beta blocker group by 0.03 W 
(P= 0.96), the mean peak CO was lower by 0.13 l/min (P=0.54) and the mean peak 
MBP was lower by 3.72 mmHg (P=0.23). However, significant differences were 
present between the mean peak HR and mean peak SV between the groups. The 
mean peak HR was lower in the beta blocker group by 26.85 min-1 (P<10-3), whereas 
the mean peak SV was greater in the beta blocker group by 26.63 ml (P<10-3) 
offsetting the reduction in peak HR. 
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3.4 Discussion 
In the present study, I tested the hypothesis that peak cardiac power and cardiac 
functional reserve are impaired in asymptomatic chronic kidney disease patients in 
the absence of any known cardiac diseases or diabetes mellitus, and the study results 
support the hypothesis. Furthermore, the peak cardiac performance was shown to be 
diminished proportional to CKD severity. As asymptomatic, non-diabetic CKD 
patients with no overt cardiac disease were studied, the results show that CKD per se 
is associated with cardiac dysfunction.  This dysfunction is only revealed under 
conditions of peak exercise, suggesting that in CKD patients, like conventional 
cardiac failure, compensatory mechanisms maintain resting cardiac performance 
within normal limits. Although cardiac structural changes have been studied in the 
past in asymptomatic CKD patients, the present study has demonstrated the 
functional impairment for the first time in such patients.  
The central haemodynamic alterations underlying the impaired peak cardiac 
performance in CKD mirror the changes in symptomatic heart failure patients albeit 
of lesser magnitude. The impairment in cardiac power results from impairment in 
both flow (peak CO) and pressure (peak MAP) generating capacities of the heart 
akin to HF. Further analysis of the components of cardiac output such as heart rate 
and stroke volume reveal impaired chronotropic reserve in CKD not unlike HF. 
Although the stroke volume appears to be preserved in CKD, a parameter that 
incorporates both volume and pressure generating capacities and is afterload-
independent such as cardiac power reveals the underlying impairment in cardiac 
contractility in CKD. In summary, the central haemodynamic changes seen in 
symptomatic heart failure appears to be evolving in asymptomatic CKD patients 
even in the absence of any primary cardiac disease.   
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Heart failure and CKD share several common pathophysiological mediators 
with the potential to cause progressive myocardial dysfunction. These include renin 
angiotensin aldosterone system (RAAS) activation, sympathetic activation, pro-
inflammatory cytokines and myocardial wall stress.84,201-205  In heart failure, these 
mediators were shown to cause direct cardiomyocyte toxicity by inducing apoptosis 
and necrosis, and pathological hypertrophy resulting in progressive myocardial 
dysfunction.115,118,206-209 The existence of the above mediators in the uraemic milieu 
raises the possibility of similar mechanism of myocardial dysfunction in CKD.  
The above similarities between CKD and HF in the biomechanics of 
myocardial dysfunction and the mediators of such dysfunction draw our attention to 
potential therapies to attenuate or reverse the process. Whereas in heart failure the 
benefits of RAAS blockade and beta blockade in preventing the progression of 
myocardial dysfunction has been shown consistently,210-212 the evidence for such 
treatments in uraemic cardiomyopathy is still lacking. 
It is interesting to note that the novel finding of the study could potentially 
explain some of the diverse phenomena shown to be associated with CKD in the 
past. It has been shown that CKD is associated with high mortality at times of stress 
such as surgery 213 or sepsis. 162 Diminished cardiac reserve in CKD could provide an 
explanation for this phenomenon. The study implies that a superimposed ischaemic 
event on a uraemic heart, with poor functional reserve, would potentially have a 
devastating effect. This has in fact been demonstrated in a large observational study 
on dialysis patients that reported an astounding 50% mortality at one year and 90% 
mortality at 5 years after a myocardial infarction.163 It is a well-established fact that 
renal dysfunction confers a serious adverse prognosis in heart failure.26 It has been 
shown that renal dysfunction is more than just a marker of severity but is an 
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independent risk factor of HF mortality.27 The finding, that renal dysfunction per se 
could cause impaired cardiac functional reserve, offers a possible pathophysiological 
explanation for the negative impact of renal dysfunction on heart failure survival. 
I utilised physical exercise to drive the heart to its peak performance because 
it is a physiological stimulus as opposed to pharmacological stimulus such as 
dobutamine. As CPX is the study tool, it is natural to assume CPOmax as being 
similar to conventional CPX parameter such as peak O2 consumption (VO2max). 
However, head-to-head comparison between VO2max and CPOmax in heart failure 
studies have demonstrated that CPOmax is a direct indicator of cardiac dysfunction 
and the best predictor of survival in patients with failing heart.153,154 Some of the 
CPX studies in end stage renal disease have suggested that conventional CPX 
parameters could serve as a measure of cardiac reserve in this population.158 The 
premise is that VO2 is a product of cardiac output and arterio-venous difference in 
oxygen concentration [VO2= CO x C(a-v)O2] and hence VO2 could serve as a 
surrogate of CO. This simplified model assumes that C(a-v)O2 is a constant 
irrespective of patient group. However, as demonstrated in the present study, C(a-
v)O2 at peak exercise is reduced in CKD compared to healthy controls [Fig 3.9].  
This impaired peripheral O2 extraction is likely to be related to anaemia (which the 
study data support), plus possible uraemic skeletal myopathy, though further studies 
would be required to fully elucidate the role of central, peripheral and biochemical 
determinants of this phenomenon. Whatever the cause, the findings of the study 
indicate that VO2max would be a less reliable indicator of cardiac reserve in CKD 
patients. 
Cardiac power output and cardiac reserve were not shown to be influenced by 
beta blockade therapy. The reduction in peak heart rate associated with beta blockade 
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was shown to be offset by the increase in SV and hence there was no net effect on 
the cardiac performance. Almost all CKD patients were treated with RAAS 
blockade, but if this has affected the results, the effect was uniform. Furthermore, as 
cardiac output and afterload have a linear inverse relationship,214 and CPOmax is an 
index that incorporates measures of both volume and pressure, the changes in arterial 
pressure are offset by changes in the volume generated. Hence CPOmax remains 
afterload-independent akin to other pressure-volume indices such as stroke work, 
stroke work index etc.214  
3.5 Limitations 
As the first ever study exploring the impact of CKD directly on peak cardiac power, I 
utilised a cross-sectional study design. A longitudinal study design in the same 
patients as the disease progresses would be better suited to demonstrate a causal 
relationship between uraemia and cardiac dysfunction. However, most etiologies of 
CKD (especially in the absence of co-morbid CVD or DM) run an indolent course 
progressing over many years making such a study challenging to undertake. 
Alternatively, a longitudinal study design testing intervention such as kidney 
transplantation or novel dialysis strategies would be highly pertinent in the future.  
 The absence of data on renal function of healthy volunteers is a 
limitation. However, as the prevalence of severe CKD (CKD 4 and 5) in general 
population is less than 1%,15,215 the likelihood of undiagnosed severe CKD among 
the healthy controls is very minimal.  
A criticism of employing CPX in the evaluation of cardiac performance is 
that inadequate patient effort could be a confounder. In our study, the respiratory 
exchange ratio (RER) of the CKD patient in all 3 groups were > 1.1 demonstrating 
good exercise effort ensuring that the impairment in cardiac functional reserve is not 
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attributable to inadequate effort. The operator measuring CPX parameters and blood 
pressure is not blinded to the severity of CKD and I recognise this as a potential 
confounder. 
 The study has demonstrated that haemoglobin is not an independent 
predictor of CPOmax. Studies that simultaneously measured peak cardiac output and 
VO2max before and after erythropoietin therapy/haemodilution had also shown that 
altered haemoglobin affected VO2max measures but not peak cardiac output.216 
Though it must be acknowledged my evaluation is limited to statistical analysis of a 
cross sectional study. Further longitudinal studies in CKD may be worthwhile in the 
future to evaluate the effect of anaemia correction on central haemodynamics. 
CKD patients suffer from metabolic acidosis. Although the effect of acidosis 
and alkalosis on the O2 dissociation curve is well known, the effect on the CO2 
dissociation curve has not been well studied. Hence, it is not known whether 
metabolic acidosis in CKD affects the non-invasive cardiac output values obtained 
by CO2 rebreathing method in CKD patients. 
3.6 Conclusion 
The study 1 of the thesis supports the hypothesis that cardiac function is impaired in 
asymptomatic CKD patients and the dysfunction appears to be associated with CKD 
alone in the absence of any known cardiovascular co-morbidities. In the next chapter, 
I describe the effect of renal transplantation on the subclinical cardiac dysfunction in 
CKD.  
. 
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CHAPTER 4 
 
Study 2 
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Reversal of subclinical cardiac dysfunction in asymptomatic chronic 
kidney disease patients following renal transplantation 
4.1 Introduction 
Uraemic cardiomyopathy (UCM), the characteristic heart disease of chronic kidney 
disease (CKD) progresses relentlessly with the progression of CKD. Starting dialysis 
does little to prevent the progression, let alone the reversal, of UCM.9 The treatment 
modality that has consistently shown to improve cardiovascular disease (CVD) 
morbidity and mortality in end stage renal disease (ESRD) is renal transplantation 
(RTx).217,218 The pathophysiological basis of such cardiovascular benefits are not 
fully understood.  Cardiac imaging studies have shown that LVH, the characteristic 
structural abnormality of UCM, regresses with kidney transplantation.219,220 
However, elucidation of the corresponding cardiac functional changes are still 
lacking.  
Previous echocardiographic studies on patients with impaired left ventricular 
ejection fraction (LVEF) pre-transplantation had shown improvement in (LVEF) 
post transplantation and the improvement had been variably attributed to correction 
of fluid status and anaemia.220-222 However, it is not known whether such functional 
benefits are applicable to a broader group of transplant candidates who are mostly 
asymptomatic. In Study 1 of the thesis I demonstrated the presence of subclinical 
cardiac dysfunction in asymptomatic CKD patients without known cardiac diseases 
or diabetes. In the present chapter of the thesis I evaluated whether successful renal 
transplantation, with significant improvement in renal function, reversed this 
functional deficit.  
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4.2 Methodology 
A detailed methodology is discussed in chapter 2 of the thesis. A brief methodology 
relevant to this chapter is presented here.  
Study design: A prospective study of 6 asymptomatic male CKD patients (>18 years) 
before and after renal transplantation (RTx).  
Investigations: CPX test was performed as described in the methodology section. 
The participants in Study 1 who received a RTx also underwent a second CPX test 
post RTx. The post-transplant CPX test was performed after at least 3 months to 
allow full recovery from the surgical procedure. In addition, blood samples were 
obtained to measure CKD-related biochemistry pre and post transplantation. 
Comparison between study parameters before and after transplantation was 
performed using paired sample t-test. A P value of <0.05 is considered significant.  
Results are presented as mean±SD.  
4.3 Results 
The patients had a mean age of 48.4 years. Their underlying aetiologies were IgA 
nephropathy (2 patients), polycystic kidney disease (2 patients), interstitial nephritis 
(1 patient) and reflux nephropathy (1 patient). Of the 6 patients, 3 were receiving 
ACE-i, 3 were receiving ARB and 4 were receiving beta blocker before RTx. Post 
RTx all patients were receiving Tacrolimus, 3 were receiving ACE-i/ARB and 1 was 
receiving a beta blocker. None of the patients were on corticosteroids. 
The median time to CPX testing post-transplantation was 5 months (range: 3 to 11 
months). Their eGFR improved from 12.5±4.0 mL/min before to 64.9±6.5 mL/min 
after transplantation (P=0.004).  
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The changes in CPX parameters before and after transplantation are presented in 
Table 4.1. Following transplantation all 6 patients showed increased CPOmax, with 
the overall mean CPOmax rising by 19.1% from 3.82±1.03 to 4.55±0.80 W (P=0.003) 
(Fig 4.1). The improvement in CPOmax resulted from increases in both peak mean 
arterial pressure (98.5±15.9 vs 110.8±12.3 mmHg, P=0.001) and peak cardiac output 
(17.29±2.37 vs 18.47±2.05 L.min-1, P=0.04) (Fig 4.2 & 4.4). Transplantation was 
also associated with statistically significant improvement in peak exercise heart rate 
(134.8±26.1 vs 156.8±29.1 min-1, P=0.04) (Fig 4.3). The cardiac reserve (ΔCPO) 
increased from 2.95±0.90 to 3.45±0.78 W (P=0.03). No statistically significant 
change was seen in VO2max (2.44±0.6 vs 2.62±0.45 L/min, P=NS) or haemoglobin 
(114.7±16.7 vs 127.8±10.5 g/L, P=NS). 
Differential role of the components of CPOmax  
The relative influence of change in peak cardiac output (peak CO) and change in 
peak mean arterial pressure (peak MAP) from the pre RTx to the post RTx state on 
the change in CPOmax was analysed using multiple regression analysis. The results 
showed that improvement in peak CO was the strongest predictor of improvement in 
CPOmax (β=0.74, P=0.005) vs peak MAP (β=0.39, P=0.028). The change in peak CO 
was equally influenced by the change in stroke volume (β=2.66, P=0.04) and change 
in heart rate (β=2.43, P=0.04). 
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Table 4.1 Biochemical and CPX parameters before and after kidney transplantation 
 
 Pre Post P value 
Biochemistry 
eGFR (mL.min-1) 12.5±4.0 64.9±6.5 0.00042 
Hb (g.L-1) 114.7±16.7 127.8±10.5 0.12 
Resting CPX parameters  
HRrest (min-1) 68.3±13.3 78.7±15 0.10 
MAP (mmHg) 87.1±10.9 90.5±4.3 0.54 
VO2 (L.min-1) 0.34±0.10 0.34±0.09 0.98 
CO (L.min-1) 4.16±0.98 5.35±1.19 0.03 
CPOrest (Watts) 0.84±0.24 1.08±0.23 0.02 
Peak CPX parameters  
RER 1.07±0.05 1.14±0.03 0.03 
VO2max(L.min-1) 2.44±0.60 2.62±0.45 0.21 
VO2max/kg (ml.min-1.kg-1) 27.5±5.5 29.3±2.5 0.48 
HRmax (min-1) 134.8±26.1 156.8±29.1 0.04 
MAPmax (mmHg) 98.5±15.9 110.8±12.3 0.001 
COmax (L.min-1) 17.29±2.37 18.47±2.05 0.04 
CPOmax (W) 3.82±1.03 4.55±0.80 0.003 
ΔCPO (W) 2.95±0.90 3.45±0.78 0.03 
 
Hb: haemoglobin, eGFR: estimated glomerular filtration rate, CO: cardiac output, CPOrest: resting 
cardiac power output, CPOmax: peak exercise cardiac power output, HRrest: resting heart rate, HRmax: 
peak exercise heart rate, RER: respiratory exchange ratio at peak exercise, VO2rest: resting O2 
consumption rate, VO2max: peak O2 consumption rate. P value is for paired sample t-test. 
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Fig 4.1: Peak cardiac power output (CPOmax) of CKD patients before (blue markers) and 
after (red markers) renal transplantation. All patients demonstrated improvement in CPOmax 
with transplantation.  
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Fig 4.2: Peak cardiac output (COmax) of CKD patients before (blue markers) and after (red 
markers) renal transplantation 
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Fig 4.3: Peak heart rate (HRmax) of CKD patients before (blue markers) and after (red 
markers) renal transplantation.  
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Fig 4.4: Peak mean arterial pressure (MAPmax) of CKD patients before (blue markers) and 
after (red markers) renal transplantation.  
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4.4 Discussion 
The results demonstrate that all patients showed improvement in peak cardiac power 
and cardiac reserve post RTx. The haemodynamic alterations such as impaired 
pressure and volume generating capacities and the impaired chronotropic reserve, 
demonstrated in the Study 1 of the thesis, all appear to improve post transplantation. 
The results, by demonstrating the reversal of cardiac functional deficit, complement 
the available literature that demonstrated reversal of LVH, in supporting the 
hypothesis that renal transplantation aids cardiac reverse remodelling in UCM.  
The beneficial cardiac effects of RTx are a possible consequence of alterations in 
the uraemic milieu brought about by RTx. Some of the uraemic factors that are 
potentially altered by RTx are presented below. However, further large studies are 
needed to fully elucidate the underlying mechanism of cardiac improvement post 
RTx. 
• Correction of sodium and water retention: Renal transplantation has the 
potential improve the volume status. In a group of 32 ESRD patients who had 
LV dilatation and underwent RTx, the left ventricular volume fell from 116 
±3.1 ml/m2 to 89±21 ml/m2.220 This improvement in volume status has the 
potential to alter cardiac loading conditions favourably. The reduction of 
preload and afterload are shown to cause cardiac reverse remodelling in heart 
failure.223 Similar cardiac reverse remodelling after RTx has been 
proposed.221 
• Correction of anaemia: Improved erythropoiesis after RTx corrects 
anaemia224 and some of the cardiac benefits of RTx is attributable to anaemia 
correction.221 
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• Correction of oxidant stress: Heart failure research has shown that oxidative 
stress  causes myocardial injury.69,71 It has been proposed that oxidative stress 
is a potential mediator of cardiotoxicity in CKD as well.75,225 There is 
evidence to suggest RTx reduces oxidative stress .226,227 This reduction in 
oxidative stress may confer some cardiac benefits post RTx. 
• Impact on sympathetic and RAAS activation: RTx is not shown to reduce 
sympathetic228 or RAAS activation229 hence it is less likely to play a role in 
the cardiac benefits of RTx. 
• Uraemic toxins: There is growing interest in the role of uraemic toxins, 
especially protein bound uraemic toxins (PBUTs), in the evolution of cardiac 
disease in CKD. It is pertinent to note that RTx is the only renal replacement 
therapy modality that has been shown to remove PBUTs.  The cardiotoxicity 
of uraemic toxins are discussed further in the subsequent chapters of the 
thesis. 
 
In addition to showing cardiac functional improvement, the results also showed that 
improvement in cardiac function occurred in the absence of statistically significant 
alterations in peak O2 consumption (VO2max), revealing a discordance between 
CPOmax and VO2max. This reflects the fact that VO2max is an indirect, surrogate 
marker of cardiac function and factors other than cardiac function, such as skeletal 
muscle mass and performance, haemoglobin and peripheral O2 extraction etc. act as 
important determinants of VO2max.230 The lack of improvement in VO2max in the 
present study may be related to non-cardiac factors such as lack of improvement in 
haemoglobin or muscle deconditioning. Hence, the failure of VO2max to show 
123 
 
 
improvement with RTx231 does no longer mean that cardiac dysfunction has not 
improved with RTx.  
4.5 Limitations 
In view of the small sample size I was not able to evaluate in detail the determinants 
of cardiac functional improvement brought about by renal transplantation. The small 
sample size also precluded analysis of the effects of medications. Further large 
studies would be worthwhile in the future.  
The sample size in the present study is small as I studied the participants from study 
1 with no co-morbid cardiac disease or DM who underwent renal RTx during the 
study period. The centre performs >100 renal transplantations per year. In the future 
studies, sample size can be significantly increased by not excluding patients with 
cardiovascular comorbidities or by involving multiple centres.  
The CKD patients did not have echocardiographic assessment post RTx. Therefore, 
the effect of RTx on cardiac structure was not evaluated in this cohort. 
4.6 Conclusion 
The results of study 2 of the thesis support the hypothesis that renal transplantation 
improves peak cardiac power and cardiac reserve. Further large studies are required 
in the future to evaluate in detail the factors that influence changes in cardiac 
structure, function and composition in CKD patients following RTx. 
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CHAPTER 5 
 
Study 3 
125 
 
 
Echocardiographic abnormalities of cardiac structure and function 
in asymptomatic chronic kidney disease patients and their 
association with peak cardiac performance 
5.1 Introduction 
As described in the introduction (Chapter 1) echocardiographic studies have 
shown a high prevalence of LVH in patients with CKD. The prevalence and the 
severity of LVH were shown to increase with increasing severity of CKD and helped 
establish LVH as the predominant structural characteristic of UCM.117-119 These 
structural changes were seen even in asymptomatic patients. However, their 
corresponding functional correlate was not identifiable.119 Therefore, it was not 
known whether the LVH was accompanied by normal or abnormal cardiac function. 
Hence, there remains an important unanswered question whether the cardiac 
remodelling in CKD is physiological or pathological. 
Furthermore, most echocardiographic studies in CKD did not exclude 
patients with cardiovascular comorbidities and hence it is hitherto unknown whether 
the echocardiographic abnormalities demonstrated in previous studies were a 
consequence of cardiovascular comorbidities or CKD per se. 
In study 3 of this thesis, I evaluated the cardiac structure and resting cardiac 
function of asymptomatic CKD patients without comorbid cardiac disease or 
diabetes using echocardiography.  I then correlated these findings with measures of 
cardiac (dys)function obtained by assessments of peak cardiac performance as 
discussed in Study 1 of the thesis (Chapter 2). 
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5.2 Methodology 
Study design: A cross sectional study of a subgroup of CKD patients (n=54) who 
underwent cardiopulmonary exercise testing (CPX) for Study 1. 
Investigations 
CPX: CPX were performed as discussed in the methodology section. 
Echocardiography: Echocardiography was performed by a qualified senior 
echocardiographer who was blinded to the severity of CKD of the study participants. 
A 2-dimensional study was performed in the standard parasternal long axis and short 
axis planes followed by an apical 4-chamber, apical 5-chamber and apical 2-chamber 
planes to evaluate cardiac structure and left ventricular contractility. In the 
parasternal long axis M-mode studies were performed in the left ventricle, at the end 
of the mitral tips. A frozen M-mode image was used to measure ventricular wall 
thickness and chamber size, in end diastole (EDD) at the peak of the R wave on the 
ECG and end systole (ESD) at the point of closest approximation of the posterior 
wall and the interventricular septum. Left atrial size was measured at the widest point 
during atrial diastole. Left ventricular ejection fraction (LVEF) was calculated by 
Simpson’s biplane method185 and left ventricular mass index (LVMI) was calculated 
by Devereaux method.186 The above data was utilised in evaluating the presence of 
the following 4 geometric patterns in CKD subjects. Normal LV geometry (normal 
LV mass and lower value of relative wall thickness), eccentric LV hypertrophy 
(increased LV mass and lower value of relative wall thickness), concentric LV 
hypertrophy (increased LV mass and increased relative wall thickness) and 
concentric LV remodelling (normal LV mass and increased relative wall 
thickness).232 
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Statistical analysis: Difference in echo parameters between study groups was 
evaluated using independent sample t-test. The correlation between echo and 
biochemical parameters was evaluated using Pearson’s correlation. Results are 
presented as mean±SD. P<0.05 is considered as significant. 
5.3 Results 
The body composition and age of study participants are presented in Table 5.1. The 
BMI and BSA of the CKD groups were comparable. However, the CKD 5 patients 
were older than other 2 groups. There was clear distinction in CKD related 
biochemistry between groups with varying severity of CKD (Table 5.1). No 
difference in resting systolic, diastolic or mean blood pressure existed between the 
CKD study groups (Table 5.1). 
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Table 5.1 Body composition and biochemistry of study participants 
 
BMI: body mass index, BSA: body surface area, CKD: chronic kidney disease, PTH: parathyroid 
hormone, PCR: protein creatinine ratio. 
 
 
 CKD 2-3a 
(n=17) 
CKD 3b-4 
(n=24) 
CKD 5 
(n=13) 
Age (year) 42.2±11.6 48.9±11.3 55.8±11.4 
BMI (kg/m2) 27.5±4.2 27.8±4.2 28.6±4.4 
BSA (m2) 2.06±0.16 2.00±0.19 2.06±0.12 
Systolic BP 
(mmHg) 
111.8±11.8 112.9±12.7 114.6±13.3 
Diastolic BP 
(mmHg) 
72.9±8.5 72.5±6.8 70.3±7.8 
Mean arterial 
pressure (mmHg) 
88.9±8.0 89.2±8.2 88.5±8.0 
Biochemistry 
eGFR (ml/min) 65.3±12.6 27.8±8.8 12.8±1.9 
Creatinine (umol/l) 115.3±17.7 247.8±71.3 469.2±78.4 
Urea (mmol/l) 8.6±2.4 17.7±5.5 24.9±4.5 
Haemoglobin (g/l) 14.9±1.3 13.2±1.5 12.2±1.0 
Calcium (mmol/l) 2.35±0.08 2.35±0.11 2.34±0.13 
Inorganic 
Phosphate (mmol/l) 
1.07±0.17 1.21±0.15 1.43±0.28 
PTH (pmol/l) 14.3±27.1 19.2±15.6 37.0±27.7 
Bicarbonate 
(mmol/l) 
27.3±2.9 23.6±3.4 22.3±2.4 
Urine PCR 
(mg/mmol) 
21.5±28.8 92.8±116.4 123.7±84.0 
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Left ventricular mass index (LVMI) increased with increasing severity of CKD 
There was an increasing trend in LVMI with increasing severity of CKD. LVMI in 
CKD 5 was significantly higher than that of CKD 2-3a (P=0.03) and the difference 
with CKD 3b-4 did not reach statistical significance for either of the groups either 
side (Table 5.2 & Fig 5.1). The proportion of patients with cardiac remodelling or 
left ventricular hypertrophy (LVMI >116 g/m2) increased with increasing severity of 
CKD. Only 23.1% of CKD 5 patients had a structurally normal heart compared to 
50% of CKD 3b-4 and 64.7% of CKD 2-3a (Fig 5.2). 
 
 
130 
 
 
 
 
Figure 5.1: Left ventricular mass index (LVMI) increased with increasing severity 
of chronic kidney disease (CKD). *P<0.05 vs CKD 2-3a 
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Figure 5.2: Proportion of patients with concentric remodelling or left ventricular 
hypertrophy increased with increasing severity of CKD.
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Table 5.2: Cardiac structure and function of study participants 
 CKD 2-3a 
(n=17) 
CKD 3b-4 
(n=24) 
CKD 5 
(n=13) 
Structure 
LVMI (g/m2) 77.5±21.6 90.9±37.6 103.1±39.4* 
RWT (mm) 4.24±1.12 4.25±0.94 4.77±1.15 
IVSD (mm) 9.85±2.15 10.92±2.88 12.63±2.38* 
LVEDD (mm) 46.85±4.61 47.65±6.11 47.08±6.66 
LVSD (mm) 33.92±4.35 32.88±4.84 30.93±7.74 
LA (mm) 34.31±3.92 36.96±5.20 38.15±4.65* 
Resting function 
LVFS (%) 27.6±6.6 30.84±6.96 33.81±15.84 
Proportion with LVEF 
<50% (%) 
Nil Nil Nil 
E/A ratio 1.12±028 1.08±0.37 0.84±0.32 
Proportion with E/A ratio 
<1 (%) 
17.6 45.8 69.2 
Resting CPO (W) 1.10±0.28 0.92±0.14 0.92±0.22 
Peak function 
Peak cardiac output 
(l/min) 
21.3±2.3 19.7±1.9 18.3±2.1 
CPOmax (W) 4.94±0.77 4.61±0.47 4.05±0.68* 
%CPOmax (%) 93.9±12.7 88.6±10.0 80.4±13.9* 
 
LVMI: left ventricular mass index, RWT: relative wall thickness, IVSD: interventricular 
septal dimension, LVEDD: left ventricular end diastolic diameter, LVSD: left ventricular 
systolic diameter, LA: left atrial diameter, LVFS: left ventricular fractional shortening, 
LVEF: left ventricular ejection fraction, E/A ratio: ration of early (E) to late (A) ventricular 
filling velocities, CPO: cardiac power output. *P<0.05 vs CKD 2-3a on Independent sample 
t-test. 
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Other measures of cardiac dimension amongst study groups 
Interventricular septal thickness and left atrial diameter was higher in CKD 5 
compared to CKD 2-3a (P<0.05). The difference between CKD 5 and CKD 3b-4 did 
not reach statistical significance.  The relative wall thickness (RWT), left ventricular 
end diastolic diameter and left ventricular systolic diameter were comparable 
between study groups (Table 5.2). 
Peak cardiac power output (CPOmax) decreased with increasing severity of CKD 
CPOmax in CKD 5 was significantly impaired compared to CKD 2-3a (P=0.003) and 
CKD 3b-4 (P=0.006). Figure 5.3 shows the concomitant increase in LVMI and 
decrease in CPOmax with increasing severity of CKD. 
Association between LVMI and haemodynamic parameters 
There was no statistically significant correlation between LVMI and the 
haemodynamic parameters such as CPOmax (r=-0.115, P=0.12), peak CO (r=-0.186, 
P=0.18), peak HR (r=-0.172, P=0.21) or peak MAP (r=0.08, P=0.5).  
Cardiac power-to-mass ratio in CKD  
Peak cardiac power per 100 gram of LVM showed significant positive correlation 
with eGFR (r=0.44, P=0.001) (Fig 5.4).  Peak cardiac power per 100 gram of LVM 
also showed graded decline across CKD stages with 3.28±0.9 W/100g in CKD 2-3a, 
2.83±0.9 W/100g in CKD 3b-4 and 2.13±0.8 W/100g in CKD 5 (Fig 5.5). It also 
showed significant negative correlation with urea (r=-0.48, P<10-3) and inorganic 
phosphate (r=-0.42, P=0.002), and positive correlation with bicarbonate (r=0.29, 
P=0.03). No significant correlation was seen with haemoglobin, serum calcium and 
urine protein creatinine ratio. 
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Figure 5.3: Increase in left ventricular mass index (LVMI) and decrease in peak 
cardiac power output (CPOmax) across the study groups. *P<0.05 vs CKD 2-3a on 
Independent sample t-test.
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Figure 5.4: Association between eGFR and power/100 g of LVM. R=0.44, P=0.001 
on Pearson’s correlation. 
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Figure 5.1: Cardiac power per 100 g of LVM decreased with increasing severity of 
chronic kidney disease (CKD). *P<0.05 vs CKD 2-3a on Independent sample t-test. 
  
137 
 
 
Association between LVMI and CKD-related biochemistry 
LVMI had significant negative correlation with eGFR and serum calcium, and 
significant positive correlation with urea and inorganic phosphate. There was no 
correlation with haemoglobin, parathyroid hormone, calcium and urine protein 
creatinine ratio (Fig 5.4). 
Association between left ventricular mass and demographic parameters 
Left ventricular mass correlated with BMI (r=0.31, P=0.02) and BSA (0.33, P=0.02). 
There was no correlation between LVM or LVMI with age. Relative wall thickness 
(RWT) correlated with age (0.37, P=0.007). There was no correlation between LVM 
or LVMI with systolic, diastolic and mean blood pressure. RWT correlated with 
mean blood pressure (r=0.31, P=0.03). 
Association between LVMI and antihypertensive medications 
There was no significant difference in LVMI between patients who were on ACE-i 
(n=32) compared to patients not on an ACE-i (n=22). The LVMI were 89.6±37.4 vs 
89.7±37.1 g.m-2 (P=NS). Similarly, there was no significant difference in LVMI 
between patients who were on an ARB (n=21) compared to patients not on ARB 
(n=33). The LVMI were 91.6±31.8 vs 88.4±36.7 g.m-2 (P=NS). The groups had 
comparable eGFR. There were 11 patients who were on beta blockers but the beta 
blocker group had significantly lower eGFR 21.4 ±15.5 ml/min compared to patients 
not on beta blockers 39.7±22.9 ml/min. Although the LVMI of beta blocker group 
was 22.6 g. m-2 higher compared to the non beta blocker group, controlling for 
eGFR, the difference did not reach statistical significance (P=0.058). 
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Figure 5.6: Association between left ventricular mass index (LVMI) and CKD-
related biochemical parameters. Hb: haemoglobin, Ur PCR: urine protein creatinine 
ratio. 
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5.4 Discussion 
The study supports our hypothesis that cardiac remodelling and hypertrophy occur in 
asymptomatic CKD even in the absence of co-morbid cardiac disease or diabetes. 
The prevalence of LVH and the LVMI increased with increasing severity of CKD. 
All of these asymptomatic patients had normal resting systolic cardiac function as 
evidenced by LVEF >50%. The LVMI appears to be negatively correlated with 
eGFR and positively correlated with urea and inorganic phosphate. No correlation 
existed with haemoglobin, urine protein creatinine ratio, serum bicarbonate, calcium, 
and calcium and phosphate product. 
 As discussed in Chapter 1 (section 1.5.2), an important characteristic that 
differentiates physiological/adaptive hypertrophy from pathological/maladaptive 
hypertrophy is the cardiac function. Whereas adaptive hypertrophy results in normal 
or supra normal function, maladaptive hypertrophy results in impaired cardiac 
function. The results of the present study demonstrate that the cardiac power-to-mass 
ratio is positively correlated with the eGFR. There is also graded decline across the 
CKD stages (Fig 5.5). Although the left ventricle appears to be hypertrophied in 
CKD, power per gram of left ventricular myocardium is significantly impaired 
especially in advanced CKD thus demonstrating the presence of pathological or 
maladaptive LVH.  
Advances in heart failure research has revealed several possible mediators of 
pathological cardiac hypertrophy118 and it is pertinent that most of these mediators 
are active in CKD as well, the most important stimulus being cardiac wall stress.205 
CKD causes renin angiotensin aldosterone system activation (RAAS), and sodium 
and water retention that leads to increased cardiac preload and afterload, in other 
words, volume and pressure overload respectively. The adaptation to the former is 
140 
 
 
eccentric hypertrophy aimed at increasing stroke volume and the latter is concentric 
hypertrophy aimed at minimizing the wall stress. The initial adaptive changes aimed 
at optimizing cardiac performance later become maladaptive leading to myocardial 
dysfunction. The precise mechanisms responsible for the transition from adaptive 
hypertrophy to maladaptive heart failure are not known, but there are several 
candidate mechanisms. Deficiencies in high-energy phosphate stores, defects in 
excitation-contraction coupling and excess formation of myocyte microtubules, 
which impairs sarcomere shortening are some of the proposed mechanisms.233-235 
Evidence exists demonstrating impaired cardiac energetics137 and defective 
excitation-contraction coupling in uraemia.140  
In addition, there are several neurohumoral mediators that are active in CKD 
with the potential to cause pathological hypertrophy. These include noradrenalin, 
angiotensin, endothelin, fibroblast growth factor and proinflammatory 
cytokines.84,201,203 These mediators, in heart failure, appear to act through various 
signal transduction proteins to activate a family of enzymes that induce the ‘fetal 
gene program’.236 Fetal gene program represents an induction of a ‘fetal’ pattern of 
gene expression, whereby certain contractile, calcium-handling, and counter-
regulatory proteins revert to the mRNA and protein expression pattern that 
characterizes the fetal stage of development. The net result of these changes is 
reduced myofilament ATPase activity and contractile velocity leading to myocardial 
dysfunction.237 The myocardial dysfunction in turn leads to reduced cardiac output 
and further stimulation of the neurohumoral system setting up a vicious cycle (Fig 
5.7) causing progressive failure of the myocardium.118 
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Figure 5.7: Vicious cycle of pathological hypertrophy and myocardial dysfunction.118
 
Drugs that block the neurohumoral activation such as beta receptor 
blockers and ACE inhibitors, that are shown to reverse this pathological remodelling, 
are the cornerstone of heart failure management.210-212 However, the evidence for 
such treatment in uraemic cardiomyopathy is still lacking.
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5.5 Limitations 
As the study is cross sectional in nature it did not allow detection of transition from 
adaptive to maladaptive hypertrophy and the factors affecting it. A longitudinal study 
evaluating such transition would be worthwhile in the future. Furthermore, only 
routine echocardiographic assessment was performed on the study subjects and 
hence detailed description of diastolic dysfunction is not available. Techniques such 
as myocardial speckle tracking or tissue doppler imaging could offer further 
information in future studies.  
I acknowledge that echocardiographic measures of cardiac dimensions are subject to 
inter observer variability. The echocardiographic assessment in the present study was 
performed by a senior echocardiographer who was blinded to the severity of CKD of 
the study subjects that helped in minimising bias.  Further evaluation using cardiac 
MRI would be worthwhile in the future to obtain more accurate information on 
cardiac size as well as cardiac composition.  
Although the use of anti hypertensive medication is not found to be a confounder in 
the association between LVMI and renal function in the present study, further 
longitudinal studies are required to evaluate the long-term effects of medications 
such as ACE-i, ARB or beta blocker on LVMI in CKD. 
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5.6 Conclusion 
The study demonstrated the presence of cardiac remodelling and hypertrophy in 
asymptomatic CKD patients even in the absence of cardiovascular comorbidities. 
The study also showed concomitant cardiac dysfunction suggesting a pathological 
hypertrophy. Further studies are needed to explore the mechanisms of pathological 
hypertrophy in CKD, and the benefits of existing heart failure therapies and the 
development of novel interventions. 
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CHAPTER 6 
 
Study 4 
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Association between cardiac dysfunction and protein bound uraemic 
toxins in asymptomatic chronic kidney disease patients 
6.1 Introduction 
Cardiovascular disease (CVD) is the predominant cause of mortality and morbidity 
in chronic kidney disease (CKD) and end stage renal disease (ESRD). Several 
pathophysiological mechanisms are being studied to understand the mechanism of 
CVD in CKD. Among the potentially putative agents of CVD, there is an emerging 
body of evidence demonstrating the role of elevated levels of protein bound uraemic 
toxins (PBUTs) such as indoxylsulphate (IXS), p-cresylsulphate (PCS), p-cresyl 
glucuronide (PCG), hippuric acid, indole acetic acid, CMPF etc.225,238-241  
There are over 30 PBUTs identified so far with their protein binding varying 
from 10% (e.g., PCG) to >9O% (e.g., IXS). It is the free (unbound) fraction that is 
biologically active and elicits toxicity. Of the PBUTs, indoxyl sulphate (IXS) and p-
cresyl sulphate (PCS) are the most studied toxins.91 They are shown to elicit a wide 
range of toxicity such as endothelial dysfunction, vascular calcification and induction 
of oxidative stress.93-95 96,97 More importantly, clinical studies have shown that IXS 
and PCS are associated with cardiovascular and all-cause mortality.95,98 Furthermore, 
serum IXS levels were shown to be associated with incidence of heart failure in CKD 
patients.242 However, the association between cardiac dysfunction and PBUTs has 
not yet been studied. 
In Study 4 of this thesis, I evaluated the association between impaired peak 
cardiac function and the serum free and total concentrations of potentially 
cardiotoxic PBUTs.  
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6.2 Methodology 
Full methodology is presented in chapter 2 of the thesis. A brief methodology 
relevant to this chapter is presented here. In a subset of 56 CKD patients (stages 2-5), 
who participated in study 1 of the thesis, we measured both CPOmax and serum levels 
of protein-bound uraemic toxins to evaluate the association between them. 
Cardio-pulmonary exercise tests (CPX) 
Peak cardiac power was measured using non-invasive maximal cardiopulmonary 
exercise testing as described in Chapter 2.  
Protein-bound uraemic toxin assays 
Sample collection: blood samples were obtained from study subjects prior to CPX 
exercise testing. The samples were immediately centrifuged and the serum stored as 
0.5 ml aliquots in a -80°C freezer. Indoxylsulphate (IXS), p-cresyl sulphate, p-cresyl 
glucuronide, indole acetic acid, hippuric acid, uric acid and 3-carboxy-4-methyl-5-
propyl-2-furanpropionic acid (CMPF) were assayed in Ghent University Hospital, 
Ghent, Belgium as described in the previously published methodological papers 
90,243. 
HPLC Analysis: chromatographic analyses were performed on the above stored 
serum samples. For quantification of the total fraction, serum samples were 
deproteinised by heat (95°C, 30 min). After cooling (10 min on ice), samples were 
filtered through a Centrifree-filter (cut-off: 30 kDa; Millipore, Billerica, MA). The 
ultrafiltrate was injected onto the column. To determine the free fraction, untreated 
serum samples were ultrafiltered prior to heating. Indoxyl sulphate, indole-3-acetic 
acid, p-cresyl sulphate and p-cresyl glucuronide were detected by fluorescence, while 
hippuric acid, CMPF and uric acid were detected by UV [Waters Alliance 2695 
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device (Waters, Zellik, Belgium) connected to a Waters fluorescence and a UV 
detector]. 
6.2.1 Statistical analysis 
Clinical study: CPOmax was the primary outcome measure. Statistical analysis was 
performed as described in Chapter 2 (page 80). 
6.3 Results 
Patient characteristics 
There were 56 male CKD patients with a mean age of 46.8±12.5 years covering the 
spectrum of CKD from stages 2 to 5 (CKD 2-5, pre-dialysis). The mean eGFR was 
38.5±24.1 ml/min. The eGFR, and the free and total (protein bound) concentrations 
of the uraemic toxins are presented in Table 6.1. 
Association between CPOmax and uraemic toxins 
The correlation between CPOmax and total and free concentrations of uraemic toxins 
are shown in Figures 6.2 and 6.3 respectively. Indoxyl sulphate (IXS) and p-cresyl 
sulphate showed strong negative correlation with CPOmax (Fig 6.2 & 6.3). No 
correlation existed between CPOmax and total or free concentrations of uraemic 
toxins such as p-cresyl glucuronide, indole acetic acid, hippuric acid, uric acid or 3-
carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF). A multivariate analysis 
[using the partial least squares (PLS) multiple regression method] was performed and 
the following uraemic toxins were found to be associated with CPOmax independent 
of eGFR, all P<0.05 (β, standardized co-efficient in brackets): free indoxyl sulphate 
(IXS) (-0.25), free p-cresyl sulphate (PCS) (-0.32), total IXS (-0.24) and total PCS (-
0.36). 
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Table 6.1 Total and free concentrations of the assayed protein-bound uraemic toxins 
across CKD groups (n=56). 
 
 
CKD 2-3a 
(n=20) 
CKD 3b-4 
(n=25) 
CKD 5 
(n=11) 
eGFR (ml/min) 66.9±12.5 27.4±8.9 11.9±2.4 
Uraemic toxins  
IXS (mg/dl) 
Total 0.10±0.05 0.37±0.21 1.44±1.13 
Free 0.002±0.001 0.009±0.005 0.05±0.05 
PCS (mg/dl) 
Total 0.35±0.23 1.21±0.9 1.67±1.04 
Free 0.009±0.006 0.029±0.023 0.043±0.031 
PCG (mg/dl) 
Total 0.01±0.01 0.024±0.02 0.09±0.1 
Free 0.004±0.004 0.019±0.016 0.077±0.114 
IAA (mg/dl) 
Total 0.04±0.01 0.10±0.06 0.12±0.12 
Free 0.003±0.001 0.011±0.009 0.018±0.018 
Hippuric acid 
(mg/dl) 
Total 0.14±0.09 0.32±0.16 0.48±0.29 
Free 0.046±0.035 0.117±0.068 0.166±0.114 
CMPF (mg/dl) Total 0.10±0.10 0.11±0.11 0.11±0.08 
Uric Acid 
(mg/dl) Total 9.65±2.43 9.86±2.29 10.36±2.19 
 
Indoxylsulphate (IXS), p-cresyl sulphate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), 
hippuric acid, uric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) 
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Figure 6.1: Association between CPOmax and total concentrations of uraemic toxins.  
Indoxylsulphate (IXS), p-cresyl sulphate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), 
hippuric acid, uric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) 
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Figure 6.2: Association between CPOmax and free concentrations of uraemic toxins.  
Indoxylsulphate (IXS), p-cresyl sulphate (PCS), p-cresyl glucuronide (PCG), indole acetic acid (IAA), 
hippuric acid, uric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) 
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Association between protein bound uraemic toxins and LVMI 
A sub group of 49 patients had echocardiographic assessment in addition to CPX. 
There was no correlation between serum levels of protein bound uraemic toxins and 
LVMI in the study cohort. 
6.4 Discussion 
The results demonstrate the independent association between protein bound uraemic 
toxins and cardiac dysfunction in CKD. Of the 30 or more protein-bound uraemic 
toxins that have previously been reported,244 we tested the leading candidates that 
might be cardiotoxic, and we found both free and total IXS and PCS were 
independently and significantly associated with subclinical cardiac dysfunction in 
CKD.  
Although it has been shown in the past that IXS is associated with incidence 
of HF in CKD,242 no association between IXS levels and LVEF or serum B type 
natriuretic peptides (BNP) were shown.245 The present study, for the first time has 
shown the association between serum IXS and PCS levels and sub clinical cardiac 
dysfunction in CKD.  
With regards to cardiac structure, a study in the past had demonstrated 
reduction in the prevalence of LVH in CKD patients treated with gut uraemic toxins 
binder AST-120.134 However, uremic toxin levels were not measured in the study. 
The association between serum uraemic toxin levels and LVH in CKD patients was 
hitherto unknown. The present study showed that there is no correlation between 
uraemic toxins and LVMI in asymptomatic CKD patients.  
IXS and PCS are generated in the gut by the action of intestinal flora on the 
substrates tryptophan and tyrosine respectively.246 These toxins are then absorbed 
and bind avidly with serum albumin. On an average 90% of these toxins are protein 
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bound. The remaining 10% unbound free toxin is biologically active.247 The normal 
mechanism of removal of these toxins by the kidneys is still being evaluated. It is 
suspected that these toxins are predominantly removed by tubular secretion with 
organic anion transporters (OAPs) playing an important role.248  
There are several potential mechanisms by which these uraemic toxins could 
elicit cardiotoxicity and some of these mechanisms have already been elucidated. In 
isolated cardiac tissue, IXS caused fibrosis and hypertrophy in neonatal rat heart99 
where inhibition of AMPK signalling was implicated.100 In adult rat hearts, fibrosis 
and hypertrophy were linked to reactive oxygen species (ROS) production and NFκB 
signaling.101 Reducing IXS levels by AST-120 (oral charcoal) reduced NFκB 
phosphorylation and fibrosis in 5/6 nephrectomy rats.102 Although the above studies 
demonstrated the role of PBUTs in inducing cardiac ultrastructural changes, studies 
on the effects of these toxins on the cardiomyocytes function are still lacking.   
 As PBUTs are mostly albumin bound, they are not as easily dialysed as 
small molecules or the middle molecules.92 Due to the protein bound nature of these 
toxins, the free serum concentration bounces back soon after dialysis. Hence these 
toxins persist in the patients’ sera and continue to elicit toxicity.92 Therefore, further 
research is needed in finding ways of reducing the uraemic toxin concentration. 
Reducing the generation of these toxins by altering diet and by adding probiotics to 
diet has been proposed.249 Intestinal adsorbents of these toxins such as AST 120 have 
been shown to reduce the levels of these toxins.249 In addition, special dialysis 
techniques designed to remove the albumin bound fraction of PBUTs have also been 
proposed.250 A prospective study of the effect of such toxin reduction strategies on 
cardiac function may be worthwhile in the future. 
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6.5 Limitations 
The cross-sectional nature of the study only allows demonstration of association 
between uraemic toxins and cardiac dysfunction. Further longitudinal studies of 
uraemic toxin reducing strategies are required to demonstrate causal relationship 
between uraemic toxin and cardiac dysfunction. 
6.6 Conclusion 
The study demonstrates the association between elevated levels of PBUTs, indoxyl 
sulphate and p-cresyl sulphate and cardiac dysfunction in asymptomatic CKD 
patients. In the next chapter I describe the effect of indoxyl sulphate on the 
mechanical properties of isolated rat cardiomyocytes. 
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CHAPTER 7 
Study 5 
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Acute effects of the uraemic toxin, Indoxyl Sulphate, on the 
mechanical properties of isolated rodent cardiomyocytes 
7.1 Introduction 
Heart failure (HF) is the predominant cardiac disease of CKD with >50% prevalence 
in end stage renal disease (ESRD).251 Dialysis does little to stop the relentless 
progression of heart disease in CKD.9 The cardiorenal interaction is mediated by 
multiple factors and there is growing interest in the role of uraemic retention solutes, 
especially protein bound uraemic toxins (PBUTs),90 as mediators of cardiotoxicity.91 
PBUTs are mostly bound to albumin and are not well cleared by dialysis and 
therefore build up in patients92 and continue to elicit toxicity in spite of dialysis. 
There is an emerging body of evidence emphasising the role of protein bound 
uraemic toxins such as indoxylsulphate (IXS), p-cresylsulphate, p-cresyl 
glucuronide, indole acetic acid, hippuric acid, etc in cardiovascular disease of 
CKD.225,238-241 The deleterious effects of some of these toxins have been well 
studied.91 The vasculotoxicity of IXS, an indole, is demonstrated by its ability to 
cause endothelial dysfunction, vascular calcification and induction of oxidative 
stress.93-95. Clinical studies have shown that IXS is associated with vascular 
calcification and vascular stiffening. The uraemic toxin has also been shown to 
predict cardiovascular and all-cause mortality.95,98 Furthermore, IXS has been shown 
to be associated with cardiac dysfunction252 in CKD and the incidence of de-novo 
heart failure in end stage renal disease (ESRD).253 In addition, reducing circulating 
levels of IXS is shown to prevent the progression of left ventricular hypertrophy in 
patients with CKD. 134 
156 
 
 
In animal studies, IXS has been shown to cause fibrosis and hypertrophy in 
isolated neonatal rat heart.99,100  In adult rat hearts, fibrosis and hypertrophy were 
linked to reactive O2 species (ROS) production and NFκB signalling.101 AST-120 
(oral charcoal) reduced IXS, NF-κB phosphorylation and fibrosis in 5/6 nephrectomy 
rats.102 Although the above studies demonstrated the role of PBUTs in inducing 
cardiac ultrastructural changes, studies on the effects of these toxins and the 
associated mechanisms on the mechanical properties (i.e. the contraction) of 
cardiomyocytes are still lacking.  
In study 4 of this thesis I demonstrated the association between subclinical 
cardiac dysfunction and serum levels of IXS and PCS. Although both these toxins 
showed independent association with cardiac dysfunction, as discussed above, there 
is a significant body of evidence highlighting the cardiotoxicity of IXS compared to 
PCS. Furthermore, IXS was shown to be associated with incident HF in CKD242 
making it a suitable candidate for further in vitro evaluation. Therefore, in this 
chapter of the thesis I tested the hypothesis that IXS has direct inhibitory effect on 
the mechanical properties of isolated rat cardiomyocytes. 
7.2 Methodology 
Detailed methodology is presented in Chapter 2 of the thesis. A concise methodology 
is presented here. 
7.2.1 Cardiac myocytes collection 
Single ventricular cardiac myocytes were isolated from male Wistar rats 
(approximately 250 g). Briefly, hearts were removed following sacrifice by Directive 
2010/63/EU approved methods then Langendorff-perfused with a collagenase- and 
protease-containing solution. The ventricles and atria were then separated, and single 
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ventricular myocytes harvested. Myocytes were stored at 20–23 °C in storage 
solution (see below) and used within 10 h. 
7.2.2 Experimental solutions 
Myocytes were stored in a solution containing (in mmol/l): 130 NaCl, 5.4 KCl, 0.4 
NaH2PO4, 1.4 MgCl2·6H2O, 5 HEPES, 10 glucose, 10 taurine, 20 creatine and 0.7 
CaCl2 (pH adjusted to 7.3 with NaOH). The experimental (Tyrode) solution 
contained (in mmol/l): 137 NaCl, 5.4 KCl, 0.33 NaH2PO4, 0.5 MgCl2·6H2O, 5 
HEPES, 5.6 glucose, and 1.8 CaCl2 (pH adjusted to 7.4 with NaOH). Indoxyl 
sulphate (IXS) (Sigma-Aldrich, Bornem, Belgium) was dissolved in saline to prepare 
the (300x) stock solution. IXS stock solution was tested for lipopolysaccharide 
contamination by a kinetic chromogenic Limulus ameobyte lysate test (Lonza, 
Vervier, Belgium). The effect of indoxylsulphate (IXS) was assessed by switching 
the superfusion solution to Tyrode solution containing IXS at a final concentration of 
4.49 mg/l, the maximum reported free concentration in uraemia.188-190  
7.2.3 Measurement of myocyte contractility 
Cells were placed in a chamber on the stage of an inverted microscope (Eclipse 
TE300, Nikon, Japan) fitted with a 40x objective. The cell chamber was perfused 
with solutions from reservoirs and warmed by a heater prior to entering the chamber. 
All experiments with single myocytes were performed at 35-37 ºC. 
Cells were considered viable for experimentation if they appeared rod shaped 
with clear striations and were quiescent in the absence of stimulation. A video image 
of the cells was acquired using a camera (MyoCam-S, IonOptIx, USA) mounted to 
the side port of the microscope and displayed on a computer monitor. Sarcomere 
length (SL) was measured by fast Fourier transform of an area of the cell, giving the 
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dominant frequency of oscillations in contrast between light and dark bands. This 
was automatically converted to a length in microns using IonWizard software 
(IonOptIx, USA). The cells were field stimulated via platinum bath electrodes using 
a 5 ms pulse and at a stimulation frequency 1 Hz.  Diastolic SL, systolic SL, 
fractional shortening (defined as a percentage change in diastolic SL) and the time 
constant of an exponential fit to the time course of the relaxation (Tau) were 
measured by averaging 10 – 15 contractions in each cell. 
7.2.4 Inhibition of Protein Kinase A 
To inhibit the action of protein kinase A (PKA), cells were incubated in storage 
solution with 100 µmol/l Rp8-Br-cAMPS (Rp8, Santa Cruz Biotech, USA), for at 
least 30 minutes. The efficacy of Rp8 in inhibiting PKA activity in our experimental 
setting was verified by assessing its ability in blunting the positive inotropic effect of 
isoproterenol (Iso, 10 nmol/1), a non-specific β-adrenoceptor agonist. 
7.2.5 Statistical analysis 
Data are expressed as mean ± SEM. Statistical significance was tested using repeated 
measures ANOVA and independent sample t-tests where appropriate using SPSS 
statistics software version 17 (IBM, USA). Statistically significant differences were 
assumed when P < 0.05. Myocyte numbers for each experiment are given in the 
relevant figures and tables. 
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7.3 Results  
7.3.1 Effect of IXS on the contraction of ventricular myocytes 
Representative traces of cardiomyocyte contractions 
Fig 7.1 shows a representative recording of the change in sarcomere length (SL) 
during exposure to and after wash out of IXS allowing the envelope of diastolic and 
systolic SL changes to be seen. Representative single contractions are shown in Fig. 
7.2 & 7.3.  
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Figure 7.1: Representative example of the effect of exposure to and wash out of IXS 
on the sarcomere length (SL) of a single rat ventricular myocyte. Stimulation 
frequency 1 Hz, 37 ºC  
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Figure 7.2 A single contraction and relaxation cycle in control (Con) and IXS. 
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Figure 7.3 Single contraction with normalised shortening to demonstrate speed of 
relaxation in IXS and Control. 
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Change in mechanical properties of cardiomyocytes on exposure to IXS 
Mean data for 26 cells from 8 animals are given in Table 7.1. Fig 7.4 gives the 
changes in SL (no of folds) during exposure to IXS compared to pre-exposure and 
after wash out. Exposure to IXS significantly lengthened diastolic SL and shortened 
systolic SL, thus the amplitude of contraction was significantly increased. IXS also 
caused a significant lusitropic effect, speeding relaxation. Upon wash out of IXS, 
inotropic and lusitropic effects reversed and SL shortening was significantly smaller 
than pre-exposure to IXS.  
 
Table 7.1 Effects of IXS on Isolated Cardiomyocytes  
 Con IXS1 IXS2 IXS5 Wash 
Diastolic Sarcomere 
Length(µm) 1.85±0.01 1.86±0.01
*#⌘ 1.86±0.01*# 1.87±0.01*# 1.85±0.02 
Fractional 
Shortening (%) 4.11±0.43 6.04±0.47
*#⌘ 5.81±0.44*# 5.1±0.40*# 3.01±0.42* 
Tau (ms) 56.0±5.31 39.5±1.20*# 40.1±2.42*# 41.7±2.28*# 57.3±3.60 
 
Mechanical properties of isolated cardiomyocytes stimulated at 1 Hz prior to exposure to IXS (Con); 
1min (IXS1), 2min (IXS2) and 5min (IXS5) following exposure to IXS and 2min after return to IXS-
free solution (Wash).  IXS caused a significant increase in diastolic sarcomere length, increase in the 
amplitude of shortening and decrease in the time constant of relaxation (Tau). Repeated Measures 
ANOVA P < 0.001. Pairwise multiple comparisons *P<0.05 vs Con, # P< 0.05 vs Wash, ⌘ P < 0.05 vs 
IXS5. (n=26 cells from 8 animals). 
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Figure 7.4 The proportional change in fractional shortening at 1min, 2min, 5min in 
IXS and 2 min after wash out compared to control at 0 min. *P<0.05 vs control 
(n=26 myocytes from 8 animals). Error bars show SEM. 
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7.3.2 Effect of IXS on the contraction of ventricular myocytes in the 
presence of Protein Kinase A (PKA) blocker  
The changes in myocyte contraction caused by IXS were characteristic of PKA 
stimulation. Therefore, the original experiment was repeated using cells treated with 
the PKA inhibitor Rp8-Br-cAMPS (Rp8).  Rp8 abolished the effect of IXS on 
fractional shortening e.g. in the absence of Rp8, after 2min in IXS, there was >60% 
increase in fractional shortening but in the presence of Rp8, there was a 0% change 
(Fig 7.5). The effects of IXS on diastolic SL (Fig 7.5) and relaxation (Fig 7.5) were 
also attenuated by Rp8 when compared to cells not treated with Rp8. The effect was 
such that in the presence of Rp8, IXS caused no significant change in fractional 
shortening, diastolic SL or speed of relaxation (Table 7.5 & Fig 7.5).  
 
Table 7.2 Effects of IXS on Isolated Cardiomyocytes treated with Rp8  
 Con IXS1 IXS2 IXS5 Wash 
Diastolic Sarcomere 
Length(µm) 1.88±0.01 1.88±0.01 1.88±0.01 1.88±0.01 1.87±0.01 
Fractional 
Shortening (%) 8.43±0.78 9.29±0.77 8.41±0.75 7.29±0.90* 5.20±1.00* 
Tau (ms) 54.5 ± 7.0 46.1±4.2 46.1±3.3 47.8±3.9 55.8±5.0 
 
Mechanical properties of isolated cardiomyocytes, treated with Rp8, stimulated at 1 Hz prior to 
exposure to IXS (Con); 1min (IXS1), 2min (IS2) and 5min (IXS5) following exposure to IXS and 
2min after return to IXS-free solution (Wash). In the presence of Rp8, the effects of IXS were 
abolished. Repeated measure ANOVA p<0.05. Pairwise multiple comparisons *P<0.05 vs Con. (n=13 
myocytes, 3 animals). 
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Figure 7.5 Changes in fractional SL shortening, diastolic SL (DSL) and time 
constant of relaxation (Tau) in response to 5min exposure to IXS and 2min wash. (Ο) 
with and (●) without 30 min prior incubation with the PKA inhibitor, Rp8. 
Normalised values relative to those prior to IXS exposure at 0 min. The figure shows 
that the effects of IXS were significantly attenuated in cells treated with the PKA 
inhibitor, Rp8. *P<0.05 vs Control for each group (pairwise multiple comparisons). 
Error bars showing SEM. (n=13 myocytes from 3 animals)  
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7.3.3 Verification of action of Rp8 
To verify the action of Rp8, cells were exposed to Isoprenaline (Iso) at a 
concentration of 10nmol/l in the presence or absence of Rp8 treatment. In the 
absence of Rp8, fractional shortening was increased from 7.34±2.08% in control to 
11.18±1.91% on exposure to Iso (P < 0.01 vs control). In the presence of Rp8, there 
was only an increase in fractional shortening from 7.79±0.92% in control to 
8.86±1.06% (P < 0.05 vs control). Thus, the effect of Iso was significantly attenuated 
by Rp8 (Fig 7.6).  
  
168 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6: Changes in fractional shortening on exposure to isoprenaline (ISO) in 
cells treated with Rp8 and cells not treated with Rp8. Rp8 is shown to attenuate the 
positive inotropic effect of ISO. *P<0.05 on independent sample t-test vs Control. 
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7.3.4 Intracellular calcium transients 
Although IXS caused a positive inotropic effect (e.g. Fig. 7.1&7.2) there was no 
corresponding increase in the [Ca2+]i transient (Table 7.3). 
Table 7.3 Effect of IXS on intracellular Ca2+ transients  
 Con IXS1 IXS2 IXS5 Wash 
Diastolic 
Calcium 
(RU) 
0.307±0.017 0.306±0.019# 0.307±0.020# 0.316±0.021 0.327±0.022* 
Calcium 
transient 
amplitude 
(RU) 
0.130±0.019 0.126±0.019# 0.127±0.019 0.115±0.017* 0.109±0.016* 
 
Characteristics of [Ca2+]i transients of isolated cardiomyocytes stimulated at 1 Hz prior to exposure to 
IXS (Con); 1min (IXS1); 2min (IXS2) and 5min (IXS5) following exposure to IXS and 2 min after 
return to IXS-free solution (Wash).  RU = ratio units. Repeated Measures ANOVA P < 0.001. 
Pairwise comparisons * P< 0.05 vs Con, # P < 0.05 vs Wash. (n = 14 myocytes from 4 animals). 
 
7.3.5 Fluorescence spectrophotometry 
The effect of IXS on the fluorescent indicator, Fura-2 was characterised. Figure 7.7 
(A) shows in vitro excitation spectra for Fura-2 at pCa 6 in the presence and absence 
of IXS. The absolute fluorescence in the presence of IXS was less than control, 
suggesting some quenching of fluorescence by IXS. The effect of IXS on the 
fluorescence ratio, our index of [Ca2+]i, is shown in Figure 7.7 (B). The data (mean 
± SEM, n = 4) were fitted to a logistic exponential curve. The fitted relationships 
suggest some flattening of the curve by IXS, though the measured ratios at each pCa 
were not significantly different from each other.  
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Figure 7.7: A Fluorescence spectra of Fura-2 free acid measured at 510 nm in 
response to excitation light between wavelengths 300nm and 400 nm at pCa6. The 
graphs show spectra in IXS (dotted line) and control (solid line) solution. The 
absolute fluorescence of Fura-2 was diminished by IXS. B 340nm/380nm ratio of 
Fura-2 in increasing calcium concentrations. The graph shows modified fitted 
relationships of the 340nm/380nm ratio to pCa in the presence of IXS (dotted line). 
n= 4 repeats in each solution.  
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7.4 Discussion 
The hypothesis, that the uraemic toxin, IXS, would induce cardiodepressant effects 
on isolated mammalian cardiac myocytes was not supported by the experimental 
results. Instead, the results showed quite the opposite, that of acute positive inotropic 
and positive lusitropic effects on isolated cardiomyocytes.  
The acute positive inotropic and lusitropic effects of IXS on cardiomyocytes 
seen in our study are similar to those seen following acute β-adrenoceptor 
stimulation254,255 which also depend upon protein kinase A (PKA) activity and 
increased intracellular levels of cyclic adenosine monophosphate (cAMP). The 
observed increase in diastolic length is compatible with decreased myofilament Ca2+ 
sensitivity as a result of PKA-dependent phosphorylation of troponin I256,257 while 
the increased inotropy and lusitropy result from PKA-dependent phosphorylation of 
Ca2+ handling proteins responsible for the entry of Ca2+ into and removal from the 
cytosol of myocytes.255  
The inhibitory effect of the PKA antagonist Rp8 on the effects of IXS 
suggests that IXS acts in a manner analogous to sympathomimetics and other 
positive inotropic agents that act upon the PKA-cAMP pathway, such as 
catecholamines and phosphodiesterase inhibitors.258 The latter two have been shown 
to be deleterious when chronically present in heart failure (HF) patients through 
progressive HF and increased mortality.259,260 The link between chronically activated 
sympathetic and renin-angiotensin-aldosterone (RAA) systems in established HF and 
cardiotoxicity of catecholamines261 and angiotensin207 is now recognized as the 
underlying mechanism responsible for progressive ventricular dysfunction in HF 
patients.262 This in turn explains the long-term beneficial effects of inhibitors of 
renin-angiotensin-aldosterone and sympathetic systems in HF therapy.211,212  
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It would appear that chronic positive inotropic effects of IXS (and potentially 
other uraemic toxins) and eventual diminution of cardiac pumping capability in CKD 
patients mirror those of catecholamines and angiotensin in HF patients. Hence, the 
experimental findings reveal that the cardiotoxicity in uraemia parallels the 
pathophysiological mechanisms underlying cardiomyopathic processes seen in 
patients with primary cardiac failure.  
7.5 Limitations 
There was no increase in the amplitude of the Fura-2 fluorescence ratio on exposure 
to IXS. This seems incompatible with a PKA-mediated mechanism of action, given 
the well-documented increase in the [Ca2+]i transient that underlies the positive 
inotropic effect of stimulating the cyclic AMP-PKA pathway in myocytes. The 
previous experiments in the lab with increasing extracellular Ca2+ has predicted that 
one should have detected an approximately 16% increase in [Ca2+]i transient 
amplitude for the observed increase in contraction caused by IXS, that is, within the 
sensitivity of the fluorescence system. However, in vitro spectrophotometry 
investigation showed that IXS quenches Fura-2 fluorescence and this may have 
influenced the in vivo measure of [Ca2+]i   Therefore, at present I interpret the lack of 
effect of IXS on the [Ca2+]i transient with caution. An explanation of the positive 
inotropic effect of IXS based on increased myofilament Ca2+-sensitivity does not 
seem credible given the longer diastolic SL and faster relaxation also observed in the 
presence of IXS.  
IXS stock solution was tested for lipopolysaccharide contamination by a kinetic 
chromogenic limulus amoebyte lysate test (Lonza, Vervier, Belgium). Therefore, 
contamination is unlikely to be a reason for the observed effect of IXS. 
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7.6 Conclusion 
In conclusion IXS has a direct effect on cardiomyocytes causing positive inotropy 
and lusitropy. IXS appears to act through PKA thus increasing the risk of 
cardiotoxicity on long-term exposure. Further research is needed to identify methods 
of reducing circulating levels of protein bound uraemic toxins. In addition, 
evaluating the effects of beta blockade in ameliorating uraemic cardiomyopathy may 
be beneficial in the future.  
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CHAPTER 8 
 
Discussion, future directions and conclusions 
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Discussion, future directions and conclusions 
8.1 Discussion 
Epidemiological studies in the 1990s7,9 highlighted the enormous impact of 
cardiovascular disease morbidity and mortality in CKD. An astounding 50% of 
ESRD patients were shown to die of CVD.263 Consequently, several research efforts 
across the globe tried to elucidate the underlying mechanisms of CVD in CKD. 
Hypertension, accelerated atherosclerosis, vascular calcification, anaemia, salt and 
water retention, and neurohumoral activation were all considered as viable 
mechanisms. However, interventions aimed at addressing the vasculopathic 
component of the cardio-vascular disease in CKD had at best shown only limited 
benefit.30-32 Hence, studies evaluating the cardiomyopathic component were 
required. Indeed, this was highly pertinent as heart failure was shown to be the 
predominant cardiac disease of CKD and ESRD.264 As a result, a report by KDIGO 
(Kidney Disease: Improving Global Outcome) in 2011 highlighted that evaluation of 
asymptomatic cardiac dysfunction is a research priority.265 Although studies using 
imaging techniques have revealed the cardiac structural characteristics in 
asymptomatic patients, its functional correlate has not been as well studied. As the 
resting cardiac function in a failing heart is kept near normal by compensatory 
mechanisms, we measured the peak cardiac performance to reveal the underlying 
myocardial dysfunction.  
The originality of the study can be summarised as follows – 
1. Peak cardiac power and cardiac functional reserve have never been measured before 
in chronic kidney disease. 
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2. These are the first studies to test a CKD cohort without pre-existing cardiac disease 
or diabetes in relation to evaluating uraemic cardiomyopathy. 
3. The differential role of cardiac output and tissue O2 extraction in determining 
exercise capacity in CKD has not been shown in CKD in the past. 
4. This is the first study to demonstrate the alterations in peak cardiac power and 
cardiac reserve with renal transplantation. 
5. This is the first study to show the association between cardiac dysfunction and 
protein bound uraemic toxins. 
6. The direct effects of indoxyl sulphate, a protein bound uraemic toxin, on the 
mechanical properties of isolated cardiomyocytes have been shown for the first time. 
Results of the studies 
Study 1 describes the results of the cross-sectional study of CKD patients, control 
subjects and heart failure patients wherein peak cardiac power was measured along 
with several biochemical and haemodynamic variables.  
Hypothesis: Peak cardiac power and cardiac functional reserve are impaired 
in asymptomatic chronic kidney disease patients in the absence of any known 
cardiac diseases or diabetes mellitus. 
I accept the hypothesis because the results demonstrated that peak cardiac power and 
cardiac reserve are impaired in asymptomatic CKD patients even in the absence of 
primary cardiac disease and diabetes. Moreover, the results showed a graded 
reduction in CPOmax in CKD patients proportional to the severity of CKD.  
 The fact that the CPOmax of CKD patients was shown to lie between that 
of healthy controls and heart failure patients is highly pertinent in understanding the 
mechanism of such cardiac dysfunction. The haemodynamic alterations in CKD 
mirrored that of heart failure patients with impaired pressure and volume generating 
capacities, impaired chronotropic reserve and impaired contractility. Thus, the 
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characteristics of heart failure were shown to be emerging in CKD even at an early 
asymptomatic stage. Although it is known that the mediators of progressive 
myocardial dysfunction in heart failure [vide infra] are also active in CKD, this is the 
first study to demonstrate the similarities in cardiac biomechanics between 
asymptomatic CKD patients and symptomatic heart failure patients.  
 The pathophysiological mediators with the potential to cause progressive 
myocardial dysfunction found in HF and CKD include renin angiotensin aldosterone 
system (RAAS) activation, sympathetic activation, pro-inflammatory cytokines and 
myocardial wall stress.84,201-205 In heart failure, these mediators were shown to cause 
direct cardiomyocyte toxicity by inducing apoptosis and necrosis, and pathological 
hypertrophy resulting in progressive myocardial dysfunction.115,118,206-209 The 
benefits of RAAS blockade and beta blockade in preventing the progression of 
myocardial dysfunction has been shown consistently210-212 in heart failure and such 
treatments form the cornerstone of heart failure management. However, similar 
studies in CKD are still lacking. The existence of cardiomyopathy in CKD means 
that such studies are worthwhile in the future. 
  
Study 2 of the thesis is a longitudinal study of alterations in peak cardiac power and 
central haemodynamics with significant improvement in renal function with renal 
transplantation.  
Hypothesis: Renal transplantation improves peak cardiac power in chronic 
kidney disease. 
Although it is a small study of 6 patients, all patients showed improvement in peak 
cardiac power and the increment resulted from improvement in pressure and volume 
generating capacities and the chronotropic reserve. Hence, I accept the above 
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hypothesis. The study demonstrated that the myocardial dysfunction of uraemic 
cardiomyopathy is potentially reversible. Further large longitudinal studies are 
required to understand the mechanism of such cardiac functional improvement.  
Study 3 of the thesis is a cross sectional study of cardiac structure in asymptomatic 
CKD patients using echocardiography. Although there were several such studies in 
the existing literature, the present study evaluated cardiac structure in asymptomatic 
subjects without confounding factors such as pre-existing heart disease or diabetes. 
Hypothesis: Cardiac structure is altered in asymptomatic chronic kidney 
disease patients in the absences of any known cardiac disease or diabetes 
mellitus. 
Whereas Study 1 showed decreasing peak cardiac power with increasing severity of 
CKD, Study 3 showed increasing left ventricular mass with increasing CKD severity. 
Hence, I accept the hypothesis. Furthermore, such an inverse relationship is 
suggestive of ‘pathological hypertrophy’ or ‘maladaptive remodelling’ in CKD.  
 Decades of heart failure research has shown that pathological 
hypertrophy can lead to myocardial dysfunction and vice versa setting in motion a 
vicious cycle leading to progressive myocardial dysfunction.118 It has also been 
shown that RAAS blockade and more importantly beta blockade can break the cycle 
and lead to reverse remodelling of the heart and restoration of myocardial 
function.118 Further studies are needed to evaluate the benefits of such strategies in 
ameliorating uraemic cardiomyopathy.  
Study 4 is a cross sectional study evaluating the association between cardiac 
dysfunction and serum levels of protein bound uraemic toxins.  
Hypothesis: Serum protein-bound uraemic toxins are inversely related to 
peak cardiac power in chronic kidney disease. 
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The ability to measure subclinical cardiac dysfunction even in early stages of CKD 
enabled evaluation of its association with a wide range of serum levels of candidate 
uraemic toxins. Indoxyl sulphate and p-cresyl sulphate were found to be 
independently associated with cardiac dysfunction. More importantly the association 
was found with the physiologically relevant free concentrations of these toxins. 
Although the result does not prove a causality the present study is the first to 
demonstrate the association between cardiac dysfunction and IXS and PCS making 
these toxins suitable candidates for further in vitro studies evaluating the mechanism 
of cardiotoxicity. 
Study 5 describes the effect of indoxyl sulphate on the mechanical properties of 
isolated rat cardiomyocytes.  
Hypothesis: Indoxyl sulphate has direct inhibitory effect on mechanical 
properties of isolated rodent cardiomyocytes. 
The experiments revealed that IXS has direct physiological effect on cardiomyocytes 
causing positive inotropy and lusitropy. Furthermore, it increased the resting 
diastolic fibre length. As these changes caused by IXS to the contractile properties 
were similar to that of protein kinase A (PKA) stimulation, further experiments were 
conducted with a PKA inhibitor. The results show that the effects of IXS were 
abolished by the PKA inhibitor suggesting that IXS acts through pathways involving 
PKA similar to other positive inotropic agents such as catecholamines and 
phosphodiesterase inhibitors. 
Based on the results I reject the above hypothesis. However, the results still offer a 
plausible pathophysiological mechanism of myocardial dysfunction in CKD. The 
positive inotropic agents such as catecholamines and phosphodiesterase inhibitors 
have been shown to be deleterious when chronically present in heart failure (HF) 
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patients as they cause progressive HF and increased mortality.259,260 It would appear 
that chronic positive inotropic effects of IXS (and potentially other uraemic toxins) 
and eventual diminution of cardiac pumping capability in CKD patients mirror those 
of catecholamines in HF patients.  
In summary, measuring peak performance instead of the resting performance of the 
heart revealed a hitherto unknown asymptomatic cardiac dysfunction in CKD. This 
ability to quantify subclinical cardiac dysfunction helped explore its association with 
novel mediators of cardiotoxicity such as protein bound uraemic toxins in a wide 
range of CKD patients and helped identify putative cardiotoxins. Further in vitro 
experiments revealed a possible mechanism of cardiotoxicity of a candidate uraemic 
toxin. Thus, the thesis describes a ‘reverse translational’ research that revealed the 
existence of true cardiomyopathy in CKD and a possible mechanism for the 
evolution of such cardiomyopathy.  
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8.2 Future directions  
Measuring peak performance of the heart has the unique advantage of revealing sub- 
clinical cardiac dysfunction thus providing a tool for studying early cardiac 
dysfunction in CKD. Furthermore, the tool can be applied in assessing cardiac 
functional benefits of various interventions. Some of the potential future applications 
of the present study are listed below. 
1. Longitudinal follow up of the study cohort to determine whether CPOmax 
predicts cardiovascular mortality and cardiovascular morbidity especially 
heart failure. 
2. Longitudinal study of CKD patients before and after kidney transplantation 
measuring CPOmax, echocardiographic parameters of cardiac structure and 
function and biochemical parameters including protein bound uraemic toxins. 
3. Longitudinal study evaluating the effect of other renal replacement therapy 
modalities such as haemodialysis and peritoneal dialysis on cardiac power 
and cardiac reserve. 
4. Evaluation of the benefits of pharmacological intervention such as beta 
blockers in effecting cardiac ‘reverse remodeling’ in uraemic 
cardiomyopathy. 
5. Evaluation of the effect of exercise training on cardiac power, cardiac output, 
tissue O2 extraction and peak O2 consumption in CKD. 
6. Further in vitro studies to assess the cardiotoxicity of other uraemic toxins. 
The effect of uraemic toxins on both mechanical and electrical properties can 
be studied using isolated cardiomyocytes and whole heart preparations.  
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8.3 Conclusion 
The research studies described in this thesis demonstrate that asymptomatic 
cardiac dysfunction, the precursor of symptomatic heart failure, is present even in 
early CKD and even in the absence of any pre-existing heart disease or diabetes. 
Further in-depth evaluation of central haemodynamics and cardiac biomechanics 
reveal the similarities between CKD and established heart failure highlighting the 
existence of true cardiomyopathy in CKD. By showing the concomitant presence of 
left ventricular hypertrophy and myocardial dysfunction, the studies suggest the 
presence of ‘pathological remodelling’ of the heart in CKD. In addition, the reversal 
of this subclinical cardiac dysfunction after renal transplantation has also been 
demonstrated. The studies also offer further mechanistic insights by demonstrating 
the association between protein bound uraemic toxins and cardiac dysfunction in 
vivo and a mechanism of cardiotoxicity in vitro. Cardiorenal studies so far have 
largely focused on the vasculopathic processes and our study highlights the existence 
of the cardiomyopathic component in the pathophysiology of the cardio-vascular 
disease of CKD and thereby emphasises the need for therapeutic strategies 
addressing such a defect.  
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